

**MEDICARE PART D: MEASURES NEEDED TO
STRENGTHEN PROGRAM INTEGRITY**

HEARING
BEFORE THE
SUBCOMMITTEE ON OVERSIGHT AND
INVESTIGATIONS
OF THE
COMMITTEE ON ENERGY AND
COMMERCE
HOUSE OF REPRESENTATIVES
ONE HUNDRED FOURTEENTH CONGRESS

FIRST SESSION

JULY 14, 2015

Serial No. 114-66



Printed for the use of the Committee on Energy and Commerce
energycommerce.house.gov

U.S. GOVERNMENT PUBLISHING OFFICE

97-834 PDF

WASHINGTON : 2016

For sale by the Superintendent of Documents, U.S. Government Publishing Office
Internet: bookstore.gpo.gov Phone: toll free (866) 512-1800; DC area (202) 512-1800
Fax: (202) 512-2104 Mail: Stop IDCC, Washington, DC 20402-0001

COMMITTEE ON ENERGY AND COMMERCE

FRED UPTON, Michigan

Chairman

JOE BARTON, Texas <i>Chairman Emeritus</i>	FRANK PALLONE, JR., New Jersey <i>Ranking Member</i>
ED WHITFIELD, Kentucky	BOBBY L. RUSH, Illinois
JOHN SHIMKUS, Illinois	ANNA G. ESHOO, California
JOSEPH R. PITTS, Pennsylvania	ELIOT L. ENGEL, New York
GREG WALDEN, Oregon	GENE GREEN, Texas
TIM MURPHY, Pennsylvania	DIANA DeGETTE, Colorado
MICHAEL C. BURGESS, Texas	LOIS CAPPS, California
MARSHA BLACKBURN, Tennessee <i>Vice Chairman</i>	MICHAEL F. DOYLE, Pennsylvania
STEVE SCALISE, Louisiana	JANICE D. SCHAKOWSKY, Illinois
ROBERT E. LATTA, Ohio	G.K. BUTTERFIELD, North Carolina
CATHY McMORRIS RODGERS, Washington	DORIS O. MATSUI, California
GREGG HARPER, Mississippi	KATHY CASTOR, Florida
LEONARD LANCE, New Jersey	JOHN P. SARBANES, Maryland
BRETT GUTHRIE, Kentucky	JERRY McNERNEY, California
PETE OLSON, Texas	PETER WELCH, Vermont
DAVID B. McKINLEY, West Virginia	BEN RAY LUJAN, New Mexico
MIKE POMPEO, Kansas	PAUL TONKO, New York
ADAM KINZINGER, Illinois	JOHN A. YARMUTH, Kentucky
H. MORGAN GRIFFITH, Virginia	YVETTE D. CLARKE, New York
GUS M. BILIRAKIS, Florida	DAVID LOEBSACK, Iowa
BILL JOHNSON, Ohio	KURT SCHRADER, Oregon
BILLY LONG, Missouri	JOSEPH P. KENNEDY, III, Massachusetts
RENEE L. ELLMERS, North Carolina	TONY CARDENAS, California
LARRY BUCSHON, Indiana	
BILL FLORES, Texas	
SUSAN W. BROOKS, Indiana	
MARKWAYNE MULLIN, Oklahoma	
RICHARD HUDSON, North Carolina	
CHRIS COLLINS, New York	
KEVIN CRAMER, North Dakota	

SUBCOMMITTEE ON OVERSIGHT AND INVESTIGATIONS

TIM MURPHY, Pennsylvania

Chairman

DAVID B. McKINLEY, West Virginia <i>Vice Chairman</i>	DIANA DeGETTE, Colorado <i>Ranking Member</i>
MICHAEL C. BURGESS, Texas	JANICE D. SCHAKOWSKY, Illinois
MARSHA BLACKBURN, Tennessee	KATHY CASTOR, Florida
H. MORGAN GRIFFITH, Virginia	PAUL TONKO, New York
LARRY BUCSHON, Indiana	JOHN A. YARMUTH, Kentucky
BILL FLORES, Texas	YVETTE D. CLARKE, New York
SUSAN W. BROOKS, Indiana	JOSEPH P. KENNEDY, III, Massachusetts
MARKWAYNE MULLIN, Oklahoma	GENE GREEN, Texas
RICHARD HUDSON, North Carolina	PETER WELCH, Vermont
CHRIS COLLINS, New York	FRANK PALLONE, JR., New Jersey (<i>ex officio</i>)
KEVIN CRAMER, North Dakota	
JOE BARTON, Texas	
FRED UPTON, Michigan (<i>ex officio</i>)	

C O N T E N T S

	Page
Hon. Timothy Murphy, a Representative in Congress from the Commonwealth of Pennsylvania, opening statement	1
Prepared statement	3
Hon. Diana DeGette, a Representative in Congress from the State of Colorado, opening statement	4
Hon. Marsha Blackburn, a Representative in Congress from the State of Tennessee, opening statement	5
Hon. Frank Pallone, Jr., a Representative in Congress from the State of New Jersey, opening statement	7
Prepared statement	8
Hon. Fred Upton, a Representative in Congress from the State of Michigan, prepared statement	66
WITNESSES	
Shantanu Agrawal, M.D., Deputy Administrator and Director, Center for Program Integrity, Centers for Medicare & Medicaid Services, Department of Health and Human Services	9
Prepared statement	12
Answers to submitted questions	74
Ann Maxwell, Assistant Inspector General, Office of Evaluation and Inspections, Office of Inspector General, Department of Health and Human Services	23
Prepared statement	25
Answers to submitted questions	85
SUBMITTED MATERIAL	
Subcommittee memorandum	68
Statement of the National Community Pharmacists Association, July 14, 2015, submitted by Mr. Murphy	72

MEDICARE PART D: MEASURES NEEDED TO STRENGTHEN PROGRAM INTEGRITY

TUESDAY, JULY 14, 2015

HOUSE OF REPRESENTATIVES,
SUBCOMMITTEE ON OVERSIGHT AND INVESTIGATIONS,
COMMITTEE ON ENERGY AND COMMERCE,
Washington, DC.

The subcommittee met, pursuant to call, at 10:02 a.m., in room 2322 of the Rayburn House Office Building, Hon. Tim Murphy (chairman of the subcommittee) presiding.

Members present: Representatives Murphy, McKinley, Barton, Burgess, Blackburn, Griffith, Bucshon, Flores, Brooks, Mullin, Hudson, Collins, DeGette, Schakowsky, Castor, Tonko, Yarmuth, Clarke, Kennedy, Green, Welch, and Pallone (ex officio).

Also present: Representative Bilirakis.

Staff present: Leighton Brown, Press Assistant; Noelle Clemente, Press Secretary; Jessica Donlon, Counsel, Oversight and Investigations; Charles Ingebretson, Chief Counsel, Oversight and Investigations; Alan Slobodin, Deputy Chief Counsel, Oversight; Traci Vitek, Detailee, Health; Jessica Wilkerson, Oversight Associate; Ryan Gottschall, Democratic GAO Detailee; Meredith Jones, Democratic Director of Communications, Member Services, and Outreach; Christopher Knauer, Democratic Oversight Staff Director; Una Lee, Democratic Chief Oversight Counsel; and Elizabeth Letter, Democratic Professional Staff Member.

Mr. MURPHY. Good morning. I convene this hearing of the Subcommittee on Oversight and Investigations.

OPENING STATEMENT OF HON. TIM MURPHY, A REPRESENTATIVE IN CONGRESS FROM THE COMMONWEALTH OF PENNSYLVANIA

We are here again today to discuss an ongoing problem with our entitlement programs—waste, fraud, and abuse—this time in the Medicare Part D program. However, the failures that we will hear about today go far beyond lost dollars and cents, rather, they are helping to feed the prescription drug abuse crisis that is gripping the country.

Medicare Part D is the fastest growing component of the Medicare program, providing approximately 39 million beneficiaries with supplemental prescription drug coverage. Given this rapid growth, Medicare Part D has been a prime target for fraud and abuse. In fact, this past June, the Department of Justice announced a nationwide Medicare fraud takedown, which led to charges against 243 individuals for approximately \$712 million in

false billings. More than 44 of the defendants were arrested on fraud related to Medicare Part D. This joint law enforcement effort, which involved the Department of Justice, the Department the Health and Human Services, the Office of Inspector General, and the FBI should be commended. But more work needs to be done at the agency level to ensure that fraudsters are not able to take advantage of the program in the first place.

Thankfully, since the inception of the Part D program, the Office of Inspector General has been working diligently to reduce waste, fraud, and abuse in the program. The OIG has released numerous reports and issued several recommendations intended to strengthen the integrity of Medicare Part D, which would save taxpayers a tremendous amount of money and would ensure that prescription drugs are being used as intended and not overprescribed or diverted.

Unfortunately, CMS has not implemented these recommendations. In its portfolio, the OIG highlighted at least nine recommendations that CMS has not implemented. All of these recommendations were issued to CMS in at least one previous OIG report, and in some instances, up to five previous reports that date back to December 2006. And these are commonsense recommendations; for example, requiring plan sponsors to report all potential fraud abuse to CMS or the Medicare Drug Integrity Contractor. This recommendation was issued in five different OIG reports.

Another important recommendation: implement an edit to reject prescriptions written by providers who have been excluded from the Medicare program. That makes sense. Yet CMS hasn't taken action to implement these recommendations. And just 6 weeks ago, one of today's witnesses, Dr. Agrawal, testified before this subcommittee and said, "holding our feet to the fire is appropriate," and when asked about fraud occurring under CMS' watch, and as I said, that's precisely what we are going to be doing today.

CMS' failure to implement these recommendations has led to trends of questionable billing associated with pharmacies, prescribers, and beneficiaries. In fact, in its Data Brief, which analyzed prescription drug events, OIG found that a lot of questionable billing was tied to commonly abused opioids.

This subcommittee has held a series of hearings examining the growing problem of prescription drugs and heroin addiction we know is ravaging our country. The opioid abuse epidemic resulted in a loss of 43,000 lives last year, and the problem continues to get worse.

As we examine the Medicare Part D program, it troubles me that between 2006 and 2014, the total number of beneficiaries receiving commonly abused opioids grew by 92 percent, compared to 68 percent for all drugs. Similarly, the average number of prescriptions for commonly abused opioids per beneficiary grew by 20 percent, compared to 3 percent for all drugs. Since 2006, Medicare spending for commonly abused opioids has grown faster than spending for all Part D drugs. We need to take a closer look at those numbers and make sure that this program is not contributing to this devastating epidemic.

The OIG has outlined several commonsense recommendations that CMS can implement. Now it is incumbent upon CMS to take

action and actually prevent fraud and abuse before it reaches a level that requires a nationwide takedown.

The committee is concerned that it continues to hold hearings like this one today where we see steps not taken and tools not utilized to protect the integrity of these programs as well as taxpayers' dollars. Now, we acknowledge it is the people who are committing fraud, whether they are physicians or pharmacists or other people, they are the ones we are going after, but we are listening today to the ideas of Dr. Agrawal and Ms. Maxwell of how we can do that.

So I thank our witnesses for joining us. You have the ability to save the American taxpayer massive amounts of money, and of course, save lives in this process.

It is this subcommittee's hope that we will hear concrete plans from you on how you will go about accomplishing this task. I might say, we need funds in other areas of care, and so we'd also like to hear when you make recommendations if there are some things that actually save us money that we know we need—for example, the mental health sphere—please tell us that as well.

[The prepared statement of Mr. Murphy follows:]

PREPARED STATEMENT OF HON. TIM MURPHY

I convene this hearing of the Subcommittee on Oversight and Investigations. We are here again today to discuss an ongoing problem with our entitlement programs: waste, fraud, and abuse. This time in the Medicare Part D program. However, the failures that we will hear about today go far beyond lost dollars and cents, rather, they are helping to feed the prescription drug abuse crisis that is gripping the country.

Medicare Part D is the fastest growing component of the Medicare program, providing approximately 39 million beneficiaries with supplemental prescription drug coverage. Given this rapid growth, Medicare Part D has been a prime target for fraud and abuse. In fact, this past June, the Department of Justice announced a nationwide Medicare fraud takedown, which led to charges against 243 individuals for approximately \$712 million in false billings. More than 44 of the defendants were arrested on fraud related to Medicare Part D.

This joint law enforcement effort, which involved the Department of Justice, the Department the Health and Human Services, the Office of Inspector General, and the FBI should be commended. But more work needs to be done at the agency level to ensure that fraudsters are not able to take advantage of the program in the first place.

Thankfully, since the inception of the Part D program, the Office of Inspector General has been working diligently to reduce waste, fraud, and abuse in the program. The OIG has released numerous reports and issued several recommendations intended to strengthen the integrity of Medicare Part D, which would save taxpayers a tremendous amount of money and would ensure that prescription drugs are being used as intended and not overprescribed or diverted.

Unfortunately, CMS has not implemented these recommendations. In its Portfolio, the OIG highlighted at least nine recommendations that CMS has not implemented. All of these recommendations were issued to CMS in at least one previous OIG report, and in some instances, up to five previous reports that date back to December 2006.

And these are commonsense recommendations. For example, requiring plan sponsors to report all potential fraud abuse to CMS or the Medicare Drug Integrity Contractor. This recommendation was issued in five different OIG reports. Another important recommendation: implement an edit to reject prescriptions written by providers who have been excluded from the Medicare program. That makes sense. Yet CMS hasn't taken action to implement these recommendations. Just six weeks ago, one of today's witnesses, Dr. Agrawal testified before this subcommittee and said, "holding our feet to the fire is appropriate," when asked about fraud occurring under CMS' watch, and that's precisely what we are here to do today.

CMS' failure to implement these recommendations has led to trends of questionable billing associated with pharmacies, prescribers, and beneficiaries. In fact, in its

Data Brief which analyzed prescription drug events, OIG found that a lot of questionable billing was tied to “commonly abused opioids.” This subcommittee has held a series of hearings examining the growing problem of prescription drugs and heroin addiction that is ravaging our country. The opioid abuse epidemic resulted in 43,000 lives lost last year and the problem continues to only get worse. As we examine the Medicare Part D program, it troubles me that between 2006 and 2014, the total number of beneficiaries receiving commonly abused opioids grew by 92 percent, compared to 68 percent for all drugs. Similarly, the average number of prescriptions for commonly abused opioids per beneficiary grew by 20 percent, compared to 3 percent for all drugs. Since 2006, Medicare spending for commonly abused opioids has grown faster than spending for all Part D drugs. We need to take a closer look at these numbers and make sure that this program is not contributing to this devastating epidemic.

The OIG has outlined several common sense recommendations that CMS can implement. Now it is incumbent upon CMS to take action and actually prevent fraud and abuse before it reaches a level that requires a nationwide takedown. The committee is concerned that it continues to hold hearings like this one today where we see steps not taken and tools not utilized to protect the integrity of these programs as well as our taxpayers’ dollars.

I would like to thank our witnesses for joining us -you all have the ability to save the American taxpayer massive amounts of money, and save lives in the process. It is this subcommittee’s hope that we will hear concrete plans from you on how you will go about accomplishing this task.

Mr. MURPHY. So thank you for being here today, and I now recognize the ranking member of the subcommittee, Ms. DeGette of Colorado, for 5 minutes.

OPENING STATEMENT OF HON. DIANA DEGETTE, A REPRESENTATIVE IN CONGRESS FROM THE STATE OF COLORADO

Ms. DEGETTE. Thank you so much, Mr. Chairman.

Medicare Part D represents the fastest growing component of the Medicare program overall. From 2006 to 2014, spending for Part D drugs increased by 136 percent from \$51.3 billion to \$121 billion. In the last 5 years, the OIG has reported a 134 percent increase in complaints and cases involving the Part D program. The Office of Management and Budget has declared Medicare Part D a high-error program with an estimated improper payment rate of 3.3 percent, or \$1.9 billion. That could make up the difference with the 21st Cures and the money we had to take out. P.S.

As with all Federal healthcare programs, reducing improper payments and protecting taxpayer dollars must be a priority of the Department and a priority of this committee, but here’s the part where I pile on to the chairman’s statement because it is not just about Federal taxpayer dollars, it is about all of the other problems you have with Medicare Part D.

As the chairman said, we are in the midst of a prescription drug abuse crisis. In 2013, prescription painkillers were involved in over 16,000 overdose deaths, and heroin was involved in an additional 8,200 deaths. Over 2.1 million Americans live with a prescription opioid addiction while 467,000 Americans are addicted to heroin. These are absolutely devastating numbers, and the chairman is right: this series of hearings that we have had this year has been, I think, one of the most eye-opening series of hearings that we have ever had in this committee illuminating this problem. And Part D is a part of it because drug diversion and overprescribing are serious challenges in the program.

Between 2006 and 2014, Part D spending for commonly abused opioids grew by 156 percent, which outpaced the growth of spending for all Part D drugs. Additionally, generic Vicodin was the number one prescribed drug in the Part D program in 2013.

The OIG is going to testify that investigations into Part D fraud, waste, and abuse have uncovered not only financial harm to the program but also serious medical harm to individual patients from the inappropriate prescribing and diversion of opioids as well as other prescription drugs. Complex criminal networks involving healthcare professionals, pharmacies, and street traffickers are becoming a pervasive element of Part D fraud schemes. In fact, last month, the Department announced the largest takedown in the history of the Medicare Fraud Strike Force, resulting in charges against 243 individuals involving about \$712 million in false billings. More than 44 of the defendants arrested were charged with fraud related to Part D.

So I want to take a minute to recognize both the OIG and CMS for the excellent work in achieving this important outcome and sending a message to the perpetrators that those who steal from Federal healthcare programs will pay a high price for their crimes.

I look forward to hearing from Dr. Agrawal, our perennial witness to this committee now, about what the agency has done to strengthen program integrity in Part D, particularly as it pertains to the issue of drug diversion and overprescribing. I know that the agency's Overutilization Monitoring System has already resulted in a substantial reduction in the number of opioid overutilizers in Part D, and I think this is an excellent step in the Federal effort to address the prescription drug abuse epidemic.

However, as we are going to hear from OIG today, Part D remains vulnerable to fraud, and there are additional opportunities to identify fraud, waste, and abuse. As the OIG describes, ensuring the integrity of the Part D program requires constant and proactive efforts at every level from the plan sponsors to CMS Program Integrity Contractors to the oversight role. However, CMS does not require plan sponsors to report potential fraud and abuse. In 2012, only 35 percent of plans reported such data voluntarily. In the opinion of the OIG, the low level of fraud identified by some plan sponsors raises questions about the sufficiency of their fraud and abuse detection programs.

I know, Dr. Agrawal, you will have more to tell us about this today. I think it is important, Mr. Chairman, that we follow up with the plan sponsors themselves to find out why they are not reporting this information about the fraud detection system. It would have been helpful to have them here today but perhaps we can have another hearing, and with that, I yield back. Thanks.

Mr. MURPHY. The gentlelady yields back.

I now recognize the vice chair of the full committee, Mrs. Blackburn, for 5 minutes.

OPENING STATEMENT OF HON. MARSHA BLACKBURN, A REPRESENTATIVE IN CONGRESS FROM THE STATE OF TENNESSEE

Mrs. BLACKBURN. Thank you, Mr. Chairman.

I want to say thank you to our witnesses. It is not your first appearance, and I am certain it is not going to be your last. We are so pleased to dig into this issue. The chairman spoke very well to that.

And going back to what Ms. DeGette was saying, when you look at the opioids, you have got the abuse. The beneficiaries receiving these prescriptions grew by 92 percent in 8 years. Now, common sense is going to tell you something is wrong with that. I mean, that is just common sense. And then last month we had 243 individuals charged with \$712 million in false billings. These people were also charged with money laundering, aggravated identify theft, and what these crimes highlight and what this growth highlights is basically what is happening at CMS, Dr. Agrawal, which is the pay-and-chase model, and it is just not working. My office has just completed a study going back and looking at the Inspector General reports, and I want you to know, HHS ranks as, I think it is number 4 over the past 10 years in collective abuse of—no, number 2. They are number 2 on the list, \$10.3 billion wasted. OIG has pinpointed this. And you have good suggestions. You have got nine outstanding recommendations made for CMS right now that you can do something about this, and hasn't been implemented.

Now, you are going to say we need more money. Well, guess what? When you have got a budget that is closing in on a trillion dollars and you have got \$10.3 billion worth of waste that you have done nothing about, we need to come dock you that \$10.3 billion. And by the way, that is just a 4-year window. You don't deserve more money. You don't deserve it because you're not taking good care of the taxpayer dollars that are coming your way.

What we want is to make certain that people that need a program and deserve a program and are rightfully in a program are going to receive the benefits of that program, but waste, fraud, and abuse is going to be targeted and it is going to be rooted out, and when you are given recommendations, we expect those recommendations to see an action. And don't tell me you are over-worked and don't tell me you don't have enough money because when you have got a job to do, you work until the job is done, and that is what we are wanting to see is that you are going to do your job.

So my question to you today is going to be very pointed. You have been given recommendations. Do you agree with the recommendations? What are you doing to enact those recommendations, and what is your timeline for having them completed?

And those are the questions I am going to have, Mr. Chairman. I will yield my time to whomever would like the balance of my time.

Mr. MURPHY. Is there anybody on this side who would like to speak on this?

If not, the gentlelady's time, she yields back, and now recognize the ranking member of the full committee, Mr. Pallone, for 5 minutes.

OPENING STATEMENT OF HON. FRANK PALLONE, JR., A REPRESENTATIVE IN CONGRESS FROM THE STATE OF NEW JERSEY

Mr. PALLONE. Thank you, Mr. Chairman.

The Medicare Part D program has been a great success for our Nation's seniors and for people with disabilities, and I am glad we are here today to discuss ways to strengthen and improve it.

For decades before its enactment, seniors and disabled Americans, often living on fixed incomes, struggled to afford the rising costs of prescription drugs. Now, more than 40 million Americans have access to affordable medications through the Medicare Part D program, and the ACA strengthened Part D and took crucial steps to improve affordability and access by closing the gap in coverage where beneficiaries pay the full cost of their prescriptions, known as the donut hole. Before the ACA, many beneficiaries struggled with crippling out-of-pocket costs in the coverage gap. The ACA gradually phases out the donut hole, and closes it completely by 2020. Since the law's enactment, 9.4 million seniors and people with disabilities have saved over \$15 billion on prescription drugs, an average of \$1,598 per beneficiary. In 2014 alone, nearly 5.1 million seniors and people with disabilities saved \$4.8 billion, or an average of \$941 per beneficiary. These are real dollars and real savings for Americans, allowing them to live healthier lives and have the peace of mind that they won't have to decide between putting food on the table or paying for lifesaving medications.

In addition, the ACA strengthened Medicare by improving the solvency of the program and strengthening program integrity. Notably, the law moved beyond the traditional pay-and-chase model to a preventative approach that seeks to keep fraudulent suppliers out of the program before fraud, waste, and abuse occur. For example, under the authorities in the ACA, CMS recently issued a final regulation that requires all Part D prescribers to enroll in Medicare. This will help ensure that Part D drugs are only prescribed by individuals who are qualified under State law and under the requirements of the Medicare program, and it implements a long-standing recommendation by the Department's Office of Inspector General.

The same rule also gives CMS the authority to revoke a provider's Medicare Part D enrollment status under certain circumstances, including if CMS determines that the provider represents a threat to the health and safety of Medicare beneficiaries or has a pattern of prescribing Part D drugs that is abusive.

And finally, to reduce prescription drug abuse and diversion, CMS now requires plan sponsors to implement internal controls to prevent overutilization of both opioids and acetaminophen. These steps and many others are transforming Medicare Part D program integrity efforts, making them more data-driven and risk-based, and I look forward to hearing from both the Office of Inspector General and from CMS about the important steps the Agency has taken to improve program integrity in Part D.

I also wanted to highlight the important bipartisan work of this committee to address one of the OIG's recommendations to improve Part D program integrity. In 2014, the OIG once again recommended that CMS seek statutory authority to implement a

pharmacy lock-in program that would allow prescription drug plan sponsors in Medicare Part D to develop safe prescribing and dispensing programs for beneficiaries that are prescribed high volumes of controlled substances, and I introduced legislation on this issue immediately following the OIG's earlier work, the Medicare Prescription Drug Integrity Act of 2013. I am gratified that H.R. 6, the 21st Century Cures Act, passed overwhelmingly by the House last Friday, acts on this recommendation and gives Part D plan sponsors the authority to establish these lock-in programs. This provision strikes the right balance to protect the integrity of the Part D program and improve patient safety, while carefully protecting beneficiary access. It is a strong example of what this committee can achieve when working in a bipartisan manner to implement commonsense policy solutions.

So I look forward to hearing from Assistant Inspector General Maxwell about the OIG's outstanding recommendations and from Dr. Agrawal regarding CMS' ongoing efforts to strengthen Part D.

Thank you, Mr. Chairman, for convening this hearing today. I was going to yield to—I don't know if anybody else wants the time. I guess not, so I will just yield back. Thank you.

[The prepared statement of Mr. Pallone follows:]

PREPARED STATEMENT OF HON. FRANK PALLONE, JR.

Thank you, Chairman Murphy, for holding this important hearing. The Medicare Part D program has been a great success for our Nation's seniors and for people with disabilities, and I am glad we are here today to discuss ways to strengthen and improve the program.

For decades before its enactment, seniors and disabled Americans, often living on fixed incomes, struggled to afford the rising costs of prescription drugs.

Now, more than 40 million Americans have access to affordable medications through the Medicare Part D program.

The Affordable Care Act strengthened Part D and took crucial steps to improve affordability and access by closing the gap in coverage where beneficiaries pay the full cost of their prescriptions, known as the donut hole. Before the ACA, many beneficiaries struggled with crippling out-of-pocket costs in the coverage gap.

The ACA gradually phases out the donut hole, and closes it completely by 2020. Since the law's enactment, 9.4 million seniors and people with disabilities have saved over \$15 billion on prescription drugs, an average of \$1,598 per beneficiary. In 2014 alone, nearly 5.1 million seniors and people with disabilities saved \$4.8 billion, or an average of \$941 per beneficiary.

These are real dollars and real savings for Americans, allowing them to live healthier lives and have the peace of mind that they won't have to decide between putting food on the table or paying for lifesaving medications.

In addition, the ACA strengthened Medicare by improving the solvency of the program and strengthening program integrity. Notably, the law moved beyond the traditional "pay and chase" model to a preventative approach that seeks to keep fraudulent suppliers out of the program before fraud, waste, and abuse occur.

For example, under authorities in the ACA, CMS recently issued a final regulation that requires all Part D prescribers to enroll in Medicare. This will help ensure that Part D drugs are only prescribed by individuals who are qualified under State law and under the requirements of the Medicare program, and it implements a long standing recommendation by the Department's Office of Inspector General.

The same rule also gives CMS the authority to revoke a provider's Medicare Part D enrollment status under certain circumstances, including if CMS determines that the provider represents a threat to the health and safety of Medicare beneficiaries or has a pattern of prescribing Part D drugs that is abusive.

Finally, to reduce prescription drug abuse and diversion, CMS now requires plan sponsors to implement internal controls to prevent overutilization of both opioids and acetaminophen.

These steps and many others are transforming Medicare Part D program integrity efforts, making them more data-driven and risk-based. I look forward to hearing

from both the Office of Inspector General and from CMS about the important steps the Agency has taken to improve program integrity in Part D.

I'd also like to highlight the important bipartisan work of this committee to address one of the OIG's recommendations to improve Part D program integrity. In 2014, the OIG once again recommended that CMS seek statutory authority to implement a pharmacy "lock-in" program that would allow prescription drug plan sponsors in Medicare Part D to develop safe prescribing and dispensing programs for beneficiaries that are prescribed high volumes of controlled substances.

I introduced legislation on this issue immediately following the OIG's earlier work, the Medicare Prescription Drug Integrity Act of 2013. I am gratified that H.R. 6, the 21st Century Cures Act, passed overwhelmingly by the House last Friday, acts on this recommendation and gives Part D plan sponsors the authority to establish these lock-in programs. This provision strikes the right balance to protect the integrity of the Part D program and improve patient safety, while carefully protecting beneficiary access. It is a strong example of what this committee can achieve when working in a bipartisan manner to implement commonsense policy solutions.

I look forward to hearing from Assistant Inspector General Maxwell about the OIG's outstanding recommendations and from Dr. Agrawal regarding CMS' ongoing efforts to strengthen Part D.

Thank you to the chairman for convening this hearing today, and I yield back.

Mr. MURPHY. I thank the gentleman for yielding back.

I might comment on the opening statement. You can see that I think this committee does its best work when we are united, and it is clear that that is the case today.

I also want to make sure I ask unanimous consent if any other Members want to introduce any opening statements for the record, they can do so, and without objection, those documents will be accepted.

You are now aware that the committee is holding an investigative hearing, and when doing so has the practice of taking testimony under oath. Do either of our witnesses today have any objections to testifying under oath? Both of them say no. The Chair then advises you that under the rules of the House and the rules of the committee, you are entitled to be advised by counsel. Do either of you desire to be advised by counsel during your testimony today? And both say no.

In that case, if you would please rise and raise your right hand, I will swear you in.

[Witnesses sworn.]

Mr. MURPHY. Thank you. You may be seated. Both witnesses said yes.

You are now under oath and subject to the penalties set forth in Title XVIII, section 1001 of the United States Code. You may now give a 5-minute summary of your written statement, and we will start with you, Dr. Agrawal. You may begin.

STATEMENTS OF SHANTANU AGRAWAL, M.D., DEPUTY ADMINISTRATOR AND DIRECTOR, CENTER FOR PROGRAM INTEGRITY, CENTERS FOR MEDICARE & MEDICAID SERVICES, DEPARTMENT OF HEALTH AND HUMAN SERVICES; AND ANN MAXWELL, ASSISTANT INSPECTOR GENERAL, OFFICE OF EVALUATION AND INSPECTIONS, OFFICE OF INSPECTOR GENERAL, DEPARTMENT OF HEALTH AND HUMAN SERVICES

STATEMENT OF SHANTANU AGRAWAL

Dr. AGRAWAL. Chairman Murphy, Ranking Member DeGette, and members of the subcommittee. Thank you for the invitation to discuss CMS' recent work to improve the Medicare prescription

drug program, also known as Medicare Part D. Our objective is to ensure that all Medicare beneficiaries receive the medicines they need while reducing and preventing prescription drug abuse.

We appreciate the subcommittee's continued focus on the problem of opioid abuse and efforts to combat the overutilization of prescription drugs. We also thank the OIG for its work to help us improve the Part D program.

The growth of prescription drug abuse has touched providers, pharmacies and beneficiaries in the Part D program. As this committee has heard, the problems with overutilization, drug diversion, and a variety of other issues are far reaching. The statutory construct of operating the Part D program requires CMS to work through hundreds of plan sponsors, which presents unique challenges to our program integrity efforts. It requires a coordinated, multifaceted approach to address the major players in Part D including prescribers, pharmacies, PMSs, and plan sponsors.

CMS has taken concrete actions in recent years to strengthen the Part D program and address weaknesses identified by the OIG and others. One element of these changes has been enhancing the culture around Part D to focus—to include a focus on program integrity, one that emphasizes prevention over the pay-and-chase model, instituting and implementing new administrative authorities to ensure only legitimate providers are prescribing drugs to beneficiaries, and improving collaboration and data sharing with Part D plan sponsors, law enforcement, and other stakeholders.

In particular, CMS is focused on holding sponsors, prescribers, pharmacies and our contractors accountable for prescribing that is consistent with our goals and values of providing safe, high-quality, evidence-based care.

CMS has also taken steps to protect beneficiaries by ensuring that they are receiving prescription drugs from legitimate providers. CMS has announced plans to undertake a major programmatic change which will require prescribers of drugs paid for by Part D to enroll in Medicare, just as they would in Parts A or B of the program, and have begun outreach efforts to enroll over 400,000 prescribers by January 2016. We will then begin enforcement in June 2016 by requiring plans to deny Part D prescriptions that are written by prescribers who do not meet the necessary requirements.

During the enrollment process, prescribers will be subject to the same risk-based screening requirements, which have already contributed to the removal of nearly 575,000 provider and supplier enrollments from the Medicare program since the enactment of the Affordable Care Act. This enrollment standard will directly address issues OIG has noted including prescriptions by excluded or invalid prescribers through new point-of-sale edits Part D plan sponsors will be required to implement.

CMS also has new authorities to remove problematic prescribers from the Medicare program for abusive prescribing behaviors. Together, we believe these new policies will help prevent bad actors from taking advantage of the Part D program and potentially harming beneficiaries. We are also utilizing Part D data more effectively. CMS is doing more to analyze and share data with Part D plan sponsors to enhance the detection and prevention of fraud and

overutilization in Medicare Part D. This includes the Overutilization Monitoring System, in which CMS identifies beneficiaries with potentially dangerous opioid utilization. We share a list of those beneficiaries with plan sponsors, which are then expected to use enhanced drug utilization review strategies such as case management and point-of-sale edits to prevent continued overutilization.

Further, plans are now allowed to share information about potentially dangerous beneficiary opioid use, actions that can help prevent beneficiaries from changing plans to avoid detection.

CMS has also developed high-risk pharmacy and prescriber assessments, which we produce for Part D plan sponsors. These assessments contain a list of pharmacies or prescribers identified by CMS as high risk based on a methodology which goes beyond simple outlier analysis. We provide plan sponsors with this information so they can initiate investigations and conduct audits, and ultimately terminate pharmacies or prescribers from their networks. Since 2013, plan sponsors have taken action against hundreds of pharmacies as a result of our Pharmacy Risk Assessments. Our newly implemented PLATO system allows plan sponsors to report back actions they have taken to address issues posed by pharmacies and prescribers.

We have also taken steps to improve data sharing with our colleagues in law enforcement. From January 2010 through the present, CMS made nearly 2,300 referrals to law enforcement. We are working closely with the OIG to prevent bad actors from fraudulently extracting trust fund dollars. Since 2013, CMS has been referring providers who qualify for permissive or mandatory exclusion from participation in Federal healthcare programs to the OIG for exclusion. CMS takes seriously the recommendations of the OIG and has taken strong steps to improve the integrity of the Part D program. We are committed to continue to work with the OIG, this committee, and others as we strengthen Medicare Part D.

I look forward to answering your questions. Thank you.

[The prepared statement of Dr. Agrawal follows:]

STATEMENT OF

SHANTANU AGRAWAL, M.D.
DEPUTY ADMINISTRATOR AND DIRECTOR,
CENTER FOR PROGRAM INTEGRITY
CENTERS FOR MEDICARE & MEDICAID SERVICES

ON

STRENGTHENING PROGRAM INTEGRITY IN MEDICARE PART D

BEFORE THE

UNITED STATES HOUSE COMMITTEE ON ENERGY & COMMERCE
SUBCOMMITTEE ON OVERSIGHT & INVESTIGATIONS

JULY 14, 2015

**Statement of Shantanu Agrawal, M.D., on
Strengthening Program Integrity in Medicare Part D
U.S. House Committee on Energy and Commerce
Subcommittee on Oversight and Investigations
July 14, 2015**

Chairman Murphy, Ranking Member DeGette, and members of the Subcommittee, thank you for the invitation to discuss the Centers for Medicare & Medicaid Services' (CMS) work to improve the Medicare Prescription Drug Program, also known as Medicare Part D, to ensure that all Medicare beneficiaries are receiving the medicines they need while also reducing and preventing nonmedical use of prescription drugs. I also would like to thank the Subcommittee for its focus on the consequences of the opioid epidemic and efforts to combat the overutilization of prescription drugs to treat pain.

Approximately 75 percent of all Medicare beneficiaries (or more than 41 million people) are enrolled in the Part D program (including those who are in standalone Part D plans, and those who are in Medicare Advantage plans offering a prescription drug benefit).¹ Since its inception in 2006, the Medicare Part D prescription drug benefit program has made medicines more available and affordable for Medicare beneficiaries, leading to improvements in access to prescription drugs, better health outcomes, and increased beneficiary satisfaction with their Medicare coverage.

Despite these successes, Part D is not immune from the nationwide epidemic of nonmedical prescription opioid use. The growth of nonmedical prescription-drug use has touched providers, pharmacies, and beneficiaries in the Part D program. CMS recognizes that all Part D plan sponsors face unique challenges in administering the Medicare prescription drug benefit. Plan sponsors operate under a different legal and regulatory framework than the traditional Medicare fee-for-service benefit. However, unlike Medicare Advantage plans offering a prescription drug benefit, stand-alone Part D plan sponsors face additional challenges because they manage only the drug benefit, which leaves plan sponsors without a direct relationship with the prescriber, while CMS manages the medical benefit. The ability of Medicare providers, pharmacies, and

¹ <https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MCRAAdvPartDEnrolData/Monthly-Contract-and-Enrollment-Summary-Report-Items/Contract-Summary-2015-06.html?DLPage=1&DLEntries=10&DLSort=1&DLSortDir=descending>

beneficiaries to abuse the Medicare prescription drug benefit is one symptom of the complex health care delivery system that must be addressed through broader reforms that result in better-coordinated care.

CMS has concurrently focused on strengthening beneficiary access to prescribed drugs, while also increasing our efforts to combat prescription drug fraud. Today, CMS requires Part D plan sponsors to have drug utilization review systems, policies, and procedures designed to ensure that a review of the prescribed drug therapy is performed before each prescription is dispensed to an enrollee in a sponsor's Part D plan, typically at the point-of-sale or point of distribution.² These requirements have strengthened the Part D program and reflect input from the Department of Health and Human Services (HHS) Office of Inspector General (OIG), Government Accountability Office (GAO), and other stakeholders. The Fiscal Year (FY) 2014 Part D Composite Payment Error Rate (based on Calendar Year (CY) 2012 payments) was 3.3 percent.³

To build on this progress and address additional recommendations from OIG, GAO, and others, the President's FY 2016 Budget includes several proposals that would provide CMS with additional tools to prevent inappropriate use of opioids.⁴ One proposal would give the Secretary of Health and Human Services (HHS) the authority to establish a program that would require that high-risk Medicare beneficiaries only obtain controlled substance prescriptions from certain prescribers and pharmacies, similar to requirements in many State Medicaid programs. CMS would work to ensure that beneficiaries retain reasonable access to quality services. Currently, CMS requires Part D sponsors to conduct drug utilization reviews to assess the prescriptions filled by a particular enrollee. These efforts can identify overutilization that results from inappropriate or even illegal activity by an enrollee, prescriber, or pharmacy. However, CMS's current statutory authority to take preventive measures in response to this information is limited.

² The Part D sponsor's concurrent drug utilization review program must include, but is not limited to, the following checks each time a prescription is dispensed: (1) screening for potential drug therapy problems due to therapeutic duplication; (2) age- or gender-related contraindications; (3) over-utilization and under-utilization; (4) drug-drug interactions; (5) incorrect drug dosage or duration of drug therapy; (6) drug-allergy contraindications; and (7) clinical abuse or misuse.

³ The FY 2014 Part D Composite Payment Error Rate combines four component payment error measures: the Payment Error relating to Low Income Subsidy Status; the Payment Error Related to Incorrect Medicaid Status; the Payment Error Related to Prescription Drug Event Data Validation; and the Payment Error related to Direct and Indirect Remuneration. <https://paymentaccuracy.gov/tracked/medicare-prescription-drug-benefit-part-d-2014>

⁴ FY 2016 Budget in Brief, <http://www.hhs.gov/budget/fy2016-hhs-budget-in-brief/hhs-fy2016budget-in-brief-overview.html>

The President's FY 2016 Budget also proposes to provide the Secretary with new authorities to: (1) suspend coverage and payment for drugs prescribed by providers who have been engaged in misprescribing or overprescribing drugs with abuse potential; (2) suspend coverage and payment for Part D drugs when those prescriptions present an imminent risk to patients; and (3) require additional information on certain Part D prescriptions, such as diagnosis and incident codes, as a condition of coverage. While Part D sponsors have the authority to deny coverage for a prescription drug on the basis of lack of medical necessity, there are currently no objective criteria to inform the medical necessity determination, such as maximum daily dosages, for some controlled substances, especially opioids. This proposal would allow plan sponsors to gather additional information, beyond prescriber attestation, as they determine whether a prescription should be filled. We look forward to working with the Congress on legislation to implement these important proposals.

Establishing Prescriber Enrollment in Medicare and Revocation for Abusive Prescribing

In addition to these items in the President's Budget, CMS is implementing new tools to take action against problematic prescribers. CMS has begun to implement critical safeguards to make sure that only legitimate prescribers are prescribing drugs to Part D beneficiaries. In the past, CMS and plan sponsors were limited in their ability to target individual prescribers; however, the Affordable Care Act granted additional authority related to strengthening Medicare enrollment requirements.

CMS has announced plans to use the authority granted to it in the Affordable Care Act to require most prescribers of drugs paid for by Part D to enroll in Medicare.⁵ CMS is actively working to enroll over 400,000 prescribers of Part D drugs by January 2016 and to enforce the requirement that plans deny Part D claims that are written by prescribers who do not meet the necessary requirements by June 2016. These prescribers will be subject to the same risk-based screening

⁵ Section 6405 of the Affordable Care Act requires that physicians and eligible professionals who order durable medical equipment, prosthetics, orthotics and supplies or certify home health care for beneficiaries be enrolled in Medicare. The statute also permits the Secretary to extend these Medicare enrollment requirements to physicians and eligible professionals who order or certify all other categories of Medicare items or services, including covered Part D drugs. Accordingly, CMS will require that physicians and eligible professionals who write prescriptions for covered Part D drugs must be enrolled in Medicare, or have a valid record of opting out of Medicare for their prescriptions to be covered under Part D.

requirements that have already contributed to the removal of nearly 575,000 provider and supplier enrollments from the Medicare program since the enactment of the Affordable Care Act. Requiring prescribers to enroll in Medicare will help CMS make sure that Part D drugs are prescribed by qualified individuals, and will prevent prescriptions from excluded or already revoked prescribers from being filled. Currently CMS is monitoring Part D claims data to identify provider types with a disproportionate number of unenrolled prescribers, such as dentists, and focusing our outreach strategy to target them. As we approach the implementation date, CMS and Part D sponsors will begin to target individual high volume prescribers that remain unenrolled. Upon enforcement of the enrollment requirement, CMS will require Part D plans to use point of sale edits to stop filling and paying for prescriptions from unenrolled prescribers after the affected beneficiaries have received a three month provisional supply and written notice from their plans.

CMS has established its authority to remove providers from Medicare when they demonstrate abusive prescribing patterns.⁶ CMS may revoke a prescriber's Medicare enrollment if his or her Drug Enforcement Administration (DEA) Certificate of Registration is suspended or revoked, or the applicable licensing or administrative body for any State in which a physician or eligible professional practices has suspended or revoked the physician or eligible professional's ability to prescribe drugs. A revocation for abusive prescribing would be based on criteria that demonstrate a pattern of improper prescribing and would address situations where the prescribing was not in compliance with Medicare requirements or where there were patient safety issues involved. These new revocation authorities provide CMS with the ability to remove problematic prescribers from the Medicare program and prevent them from treating people with Medicare.

Harnessing Data to Strengthen the Part D Program

CMS is doing more to use and share data with Part D plan sponsors to enhance the detection and prevention of fraud and overutilization in Medicare Part D. CMS has increased data sharing between plans and is using currently available data better as we work to strengthen the Part D

⁶ See <http://www.gpo.gov/fdsys/pkg/FR-2014-05-23/pdf/2014-11734.pdf>.

program. CMS regularly monitors pharmacy billing patterns and has initiatives in place to address the risks posed by pharmacies with questionable billing practices.

Improving Data Analysis Conducted by the Medicare Drug Integrity Contractor (MEDIC)

CMS contracts with the National Benefit Integrity (NBI) MEDIC to identify and investigate potential fraud and abuse, and develop cases for referral to law enforcement agencies. In September 2013, CMS directed the NBI MEDIC to perform more proactive data analysis, including producing, at a minimum, quarterly reports to plan sponsors on specific data projects, such as high risk pharmacies assessments.

These assessments contain a list of pharmacies identified by CMS as high risk and provide plan sponsors with information to initiate new investigations, conduct audits, and ultimately terminate pharmacies from their network. For example, one Part D plan sponsor terminated 51 pharmacies from its network as a result of the March 2015 Pharmacy Risk Assessment. Another Part D plan sponsor opened investigations on 16 pharmacies as a result of the September 2014 Pharmacy Risk Assessment.

The NBI MEDIC also conducts data analysis and other work to support ongoing law enforcement activities. Examples of the assistance that the NBI MEDIC provides includes: data, data analysis, impact calculations, clinical review of claims and medical records, and prescription drug invoice reconciliation reviews.

Ensuring Timely Access to Data

Last year, CMS finalized a rule that includes a provision to give CMS, its antifraud contractors, and OIG the ability to request and collect information directly from pharmacy benefit managers, pharmacies and other entities that contract or subcontract with Part D plan sponsors to administer the Medicare prescription drug benefit.⁷ The provision streamlines both CMS's and the contractors' investigative processes. Previously, CMS's contractors had to work through the Part D plan sponsor to obtain important documents like invoices and prescriptions, which resulted in delays in getting critical information. This provision provides more timely access to

⁷ Medicare Program; Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs, <https://www.federalregister.gov/articles/2014/05/23/2014-11734/medicare-program-contract-year-2015-policy-and-technical-changes-to-the-medicare-advantage-and-the>.

records, including information for investigations of Part D fraud and abuse, and responds to recommendations from OIG.⁸

Incorporating Part D Data in the Fraud Prevention System (FPS)

CMS is leading the government and healthcare industry in systematically applying advanced analytics to claims on a nationwide scale. Since 2011, CMS has been using its Fraud Prevention System (FPS) to apply advanced analytics on all Medicare fee-for-service (FFS) claims on a streaming, national basis by using predictive algorithms and other sophisticated analytics to analyze every Medicare FFS claim against billing patterns. The system also incorporates other data sources, including information on compromised Medicare cards and complaints made through 1 800-MEDICARE. CMS is developing ways to leverage data from the Part D program to strengthen FPS models that identify Medicare FFS providers with behaviors that require intervention. Since the FPS combines information by FFS provider, the information from Part D will not change the focus on the provider, but will be used to develop new risk factors. For example, CMS will include in the FPS a model that monitors for high-risk prescribers as one of the criteria for elevated risk. By incorporating the analysis of high-risk prescribers into the FPS, CMS will be better able to investigate and take swift action on bad actors in a coordinated way.

Using Data to Identify Outlier Prescribers

CMS used prescription drug event (PDE) data to identify 1,525 prescribers as outliers of Schedule II controlled substances in the 95th percentile for the number of prescriptions and the number of 30-day equivalent prescriptions. Using this information, CMS developed reports that clearly identified the differences in prescribing patterns for the identified outliers. Similar to CMS's comparative billing report initiatives, the goal is to: (1) proactively educate providers about aberrant prescribing practices; (2) act as a deterrent by making providers aware of the Government's monitoring of their prescribing practices; and (3) reduce inappropriate prescribing. CMS then sent these reports to half of the providers, alerting them about their status as outliers. This approach allowed us to measure the effectiveness of the letters in changing provider behavior. CMS also shared the list of outlier prescribers with Part D plan sponsors in an

⁸ See <http://oig.hhs.gov/oci/reports/oci-03-11-00310.asp>.

effort to augment their current utilization management program. We are further developing this and other approaches, using a similar analysis related to prescribing of atypical antipsychotics.

Improving Transparency in Prescriber Level Data

In April 2015, CMS released a new public use dataset on the prescription drugs that individual physicians and other health care providers prescribed in 2013 under Part D⁹. The dataset describes the specific medications prescribed and statistics on their utilization and costs. It provides data on more than one million distinct health care providers who collectively prescribed \$103 billion in prescription drugs under the Part D program. This adds to the unprecedented information previously released on services and procedures provided to Medicare beneficiaries, including hospital charge data on common inpatient and outpatient services as well as utilization and payment information for physicians and other healthcare professionals. We believe this increased transparency will give patients, researchers, and providers access to information that will help shape the future of our nation's health for the better.

On June 30, 2015, CMS posted the second set of Open Payments data,¹⁰ which provides information about financial relationships between drug and device makers and doctors and teaching hospitals. These data include 11.4 million financial transactions valued at \$6.49 billion that occurred throughout CY 2014.

Communicating and Collaborating with Plan Sponsors and Law Enforcement

Federal, state, and local law enforcement health care fraud activities are being coordinated to a greater extent than ever before. As evidence of this coordination, CMS is also taking steps to better disseminate the results of our data analytics work to Part D plan sponsors and our law enforcement partners. CMS also is engaging with the private sector in new ways to better share information to combat fraud.

For example, the Healthcare Fraud Prevention Partnership (HFPP) has made progress since its inception with the successful sharing of data and building confidence and trust among

⁹ <http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Part-D-Prescriber.html>

¹⁰ Available at <http://www.cms.gov/openpayments>.

partners. We are continuing to grow strategically by adding new partners and increasing the current reach to realize greater potential in identifying overlapping fraud schemes among partners. On April 16, 2015, CMS launched a web-based tool to allow CMS, law enforcement, and plan sponsors to share information and coordinate actions against high-risk pharmacies. This information sharing tool offers leads for potential high-risk pharmacies and providers identified through data projects that assist users in conducting investigations and other compliance program activities.

Collaboration between CMS program officials and law enforcement is a critical cornerstone for improving health care fraud detection and investigation. In addition to CMS's commitment to collaboration, the sustained success of the Health Enforcement Action Team (HEAT) demonstrates the effectiveness of the Cabinet-level commitment between HHS and the Department of Justice to prevent and prosecute health care fraud. CMS conducts analysis and monitors potentially fraudulent activity in geographic hot spots for fraud and abuse and works with the Medicare fraud strike force to focus law enforcement efforts on those areas.

Most recently, on June 18, 2015, HHS Secretary Sylvia M. Burwell and Attorney General Loretta E. Lynch announced a nationwide sweep led by the Medicare Fraud Strike Force in 17 districts, resulting in charges against 243 individuals, including 46 doctors, nurses and other licensed medical professionals, for their alleged participation in Medicare fraud schemes involving approximately \$712 million in false billings. More than 40 of the defendants arrested are charged with fraud related to the Medicare Part D program.¹¹

CMS continues to provide strong support to law enforcement. From January 2010 through the present, CMS's MEDIC made 2,275 referrals to law enforcement. Through our collaboration with OIG, CMS has also sought to prevent bad actors from fraudulently extracting Trust Fund dollars. For example, in December 2013, the NBI MEDIC began referring providers who qualify for permissive or mandatory exclusion from participation in Federal health care program to OIG for exclusion. Since 2013, the MEDIC has made 72 referrals for exclusion, of which 11

¹¹ See <http://www.hhs.gov/news/press/2015pres/06/20150618a.html>.

have been added to OIG's List of Excluded Individuals and Entities (LEIE) Exclusions Database.¹²

Oversight of Plan Sponsors

In response to OIG reports¹³ recommending that CMS have measures in place to ensure that Medicare Part D Prescription Drug Plans (PDPs) have implemented effective measures to prevent, detect, and correct fraud, waste and abuse, CMS conducted a pilot audit in 2014 to assess the maturity and effectiveness of plans' activities.

CMS identified similar trends across Part D plan sponsors that identified best practices and showed the need for improved strategies to combat fraud, waste, and abuse. CMS also determined that plan sponsors could improve their work in the area of preventative and proactive corrective actions against fraud, waste, and abuse, including fraud referrals to Law Enforcement and/or the NBI MEDIC.

As a result of the trends identified, CMS expanded the 2015 Compliance Audits to include an increased focus on fraud, waste, and abuse. CMS has shared these observations such as trends and best practices with plan sponsors during quarterly trainings with plan sponsors. The trainings provide plan sponsors with information on Part D trends, analysis, and fraud schemes, and plan sponsors also share information regarding their own fraud, waste, and abuse activities. Plan sponsor participation in these trainings has significantly increased in recent years.

Overutilization Monitoring System

To address concerns about prescription drug overutilization raised by the GAO¹⁴, CMS provides information to plan sponsors about Part D enrollees who have potential opioid or acetaminophen overutilization that may present a serious threat to patient safety. Since 2013, CMS has been using the Medicare Part D Overutilization Monitoring System (OMS) to monitor Part D plan sponsors' drug utilization management programs to prevent overutilization of these medications. Using OMS, CMS provides quarterly reports to sponsors on beneficiaries with

¹² See https://oig.hhs.gov/exclusions/exclusions_list.asp.

¹³ See <http://oig.hhs.gov/oei/reports/oei-03-13-00030.pdf> and <http://oig.hhs.gov/oei/reports/oei-03-08-00230.pdf>.

¹⁴ See <http://gao.gov/new.items/d11699.pdf>.

potential opioid or acetaminophen overutilization identified through analyses of PDE data. Sponsors are expected to use various drug utilization monitoring tools, including: (1) formulary-level controls (such as safety edits and quantity limits) at point-of-sale; (2) reviews of prior claims and clinical activity to identify at-risk beneficiaries; (3) case management outreach to beneficiaries' prescribers and pharmacies; and (4) beneficiary-level point-of-sale claim edits, if necessary to prevent continued overutilization of opioids. Lastly, Part D plan sponsors that have concluded that such point-of-sale edits are appropriate are expected to share information with a new sponsor when the beneficiary moves to another plan in accordance with applicable law.

A comparison of overutilization shows a significant reduction of opioid and acetaminophen overutilization in Part D since the overutilization policy went into effect. From 2011 through 2014, the number of potential opioid overutilizers, based on the CMS definition in the OMS, decreased by approximately 26 percent, or 7,500 beneficiaries.¹⁵ In addition, from 2011 through 2014, the number of beneficiaries identified as potential acetaminophen overutilizers, based on the CMS definition in the OMS, decreased by more than 91 percent, or 70,000 beneficiaries.¹⁶

Conclusion

CMS has an important role in the effort to combat prescription drug abuse and overutilization. We have taken steps to reduce the potential harm to Medicare beneficiaries, as well as the significant financial impact to taxpayers, of improper prescribing and potentially fraudulent activity. We are committed to working with OIG to address its recommendations as we strengthen program integrity in Medicare Part D. We look forward to working with this Subcommittee and the Congress on these efforts.

¹⁵ There were 29,404 potential opioid overutilizers, (or 0.29 percent of all Part D opioid users) in 2011 and there were 21,838 potential opioid overutilizers, (0.18 percent of all Part D Opioid users) in 2014.

¹⁶ There were 76,581 potential acetaminophen overutilizers, (or 0.81 percent of all Part D acetaminophen users), in 2011 and in 2014 there were 6,286 (0.06 percent of all Part D acetaminophen users) in 2014.

Mr. MURPHY. Ms. Maxwell.

STATEMENT OF ANN MAXWELL

Ms. MAXWELL. Good morning, Chairman Murphy, Ranking Member DeGette, and other distinguished members of the subcommittee. I am pleased to join you today to discuss how we can protect Medicare's prescription drug program from fraud and abuse.

The OIG has made a strong commitment to help safeguard Medicare Part D. Just last month, OIG special agents and other law enforcement personnel fanned out across the country to conduct the largest criminal healthcare fraud takedown ever. A number of the arrests were for doctors and pharmacy owners involved in prescription drug fraud, and there are likely to be more arrests because we have found that Part D continues to be vulnerable to fraud.

Recently, we identified 1,400 retail pharmacies with questionable Medicaid payments. In one example, a Detroit-area pharmacy billed for commonly abused pain medications—opioids, to be exact—for 93 percent of its Part D patients. As this committee is well aware, abusing opioids can lead to patient harm and even death. It is also tied to illegal drug trafficking, which is why the OIG is not stopping with the recent takedown.

As our special agents investigated and built these cases, OIG analysts were already proactively mining the data to identify new leads to help us—CMS—shut down and—target and shut down this problem.

As important as our law enforcement efforts have been, we cannot arrest our way out of this problem. We have to strengthen our defenses. OIG has several outstanding recommendations for fixing some of the systemic vulnerabilities that allow fraud and abuse to slip through undetected. To start, CMS can better leverage data as a tool to improve oversight and to keep up with the ever evolving fraud landscape. This should include collecting the data necessary to ensure that plan sponsors, the hundreds of private companies that administer the program, are effectively protecting the program. These plan sponsors are Part D's first line of defense.

Currently, as you already heard, CMS does not require these plan sponsors to report on the fraud and abuse that they identify. While plan sponsors may report this information voluntarily, given the choice, we found that less than half chose to report. Information on identified fraud and abuse as well as how sponsors handle these cases would help CMS assess the effectiveness of sponsors' efforts to protect Part D. Better leveraging data should also involve expanding the analysis of the data CMS already collects. We recommend that CMS and plan sponsors monitor payment data for a wider range of drugs prone to abuse.

CMS does have several key initiatives underway focused on opioids, and while opioid abuse is certainly a major concern, OIG has identified questionable billing patterns related to other drugs. This includes non-controlled substance, which can present a substantial financial loss to Medicare and can be abused in combination with controlled substances.

In addition to better leveraging data, plan sponsors and CMS should buttress current defenses by adding the following three oversight tools to their current efforts.

First, plan sponsors and CMS need to implement stronger payment controls to stop paying for things they shouldn't be paying for, like payments for drugs prescribed by doctors excluded from the Medicare program, or paying for illegal refills of controlled substances. Second, another powerful preventative measure would be a lock-in program that restricts certain beneficiaries to a limited number of pharmacies and prescribers. This tool allows for better monitoring to prevent at-risk beneficiaries from overutilizing drugs that might harm them or diverting those drugs for illegitimate use. Finally, we recommend that CMS improve processes to recover inappropriate Part D payments.

Our recent law enforcement and data-mining efforts show that the current defenses are not strong enough. Plan sponsors need to reinforce that first line of defense but they cannot be the only line of defense. Ultimately, it is CMS that is responsible for ensuring the integrity of Part D.

For our part, we will continue to focus our full array of resources on protecting the program, and we stand ready to work with you, with CMS and others to improve program integrity.

At this time, I am happy to be of assistance and can answer any of your questions. Thank you so much.

[The prepared statement of Ms. Maxwell follows:]



**Testimony Before the United States House of Representatives
Committee on Energy and Commerce
Subcommittee on Oversight and Investigations**

**“Medicare Part D: Measures Needed To Strengthen
Program Integrity”**

Testimony of:

**Ann Maxwell
Assistant Inspector General
Office of Evaluation and Inspections
Office of Inspector General
Department of Health and Human Services**

July 14, 2015

10 a.m.

Rayburn House Office Building, Room 2322

Testimony of:

Ann Maxwell

Assistant Inspector General for Evaluation and Inspections
Office of Inspector General, U.S. Department of Health and Human Services

Good morning, Chairman Murphy, Ranking Member DeGette, and other Members of the Subcommittee. I am Ann Maxwell, Assistant Inspector General for Evaluation and Inspections of the Office of Inspector General (OIG), U.S. Department of Health and Human Services (HHS). Thank you for the opportunity to testify about fraud, waste, and abuse trends in the Medicare Part D Program and the status of our recommendations to address the underlying vulnerabilities of the program. During my testimony, I will be drawing heavily from two OIG products, our portfolio report, *Ensuring the Integrity of Medicare Part D* (OEI-03-15-00180) and our data brief, *Questionable Billing and Geographic Hotspots Point to Potential Fraud and Abuse in Medicare Part D* (OEI-02-15-00190), both of which were issued in June 2015. With your permission, Mr. Chairman, I would like to submit both of those reports for the record.

OIG has made stopping Part D fraud a top priority. With over 39 million Americans depending on the program for their prescription drugs costing over \$120 billion a year, OIG finds it imperative to take a comprehensive approach to combat Part D fraud.

I will first describe our investigative efforts and analysis of potential fraud indicators to describe the scale of the fraud challenge in Part D. While we understand that enforcement is an important tool in addressing fraud in Part D, it cannot address the systemic changes that the Centers for Medicare & Medicaid Services (CMS) needs to make to protect the integrity of the program. In this vein, I will then provide an overview of the unimplemented recommendations OIG has made to CMS that if implemented, would significantly increase CMS's ability to improve the Part D program's effectiveness and protect its beneficiaries. I will close by suggesting action that would improve program integrity.

THE MEDICARE PART D PROGRAM IS VULNERABLE TO FRAUD

In June 2015, OIG deployed more than 300 special agents and forensic specialists, alongside hundreds of other law enforcement personnel, to execute arrest and search warrants across the country. It was the largest national health care fraud takedown to date and resulted in more than 240 subjects being charged with defrauding the Medicare and Medicaid programs involving over \$700 million in false billings. Much of the fraud involved prescription drugs and those charged included doctors, pharmacy owners, and others. Twenty-eight individuals

from South Florida alone were charged with Part D fraud totaling more than \$38 million in Medicare overpayments.

This takedown put into sharp focus the threat that fraud schemes pose to the Part D program. These schemes increasingly involve criminal networks, which have become a pervasive problem in health care fraud. Schemes include billing for drugs that are not dispensed, illegal dispensing of expired or adulterated drugs, doctor shopping, and drug diversion when a prescription drug is redirected for an illegal purpose, such as recreational use or resale. For example, two individuals arrested in the June takedown in South Florida allegedly sold diverted prescription drugs worth a total of approximately \$200,000 to undercover agents on three separate occasions. The diversion of controlled substances, such as opioids, is of particular concern due to its severe health risk and potential for abuse. However, we are also concerned with the diversion of noncontrolled substances, such as HIV and antipsychotic medications, as these drugs are becoming more common in fraud schemes. Fraud related to these drugs can harm beneficiaries and present a significant financial loss to Medicare.

OIG pursues such fraud cases through coordinated Federal and State enforcement efforts, including the Medicare Fraud Strike Force teams. During the last three years (FY 2012–2014), OIG’s Part D investigations resulted in 339 criminal actions, 31 civil actions, and over \$720 million in investigative receivables. Yet, as successful as these enforcement efforts have been, they alone do not solve the problem of prescription drug fraud. Vulnerabilities still exist in the Part D program, where spending has risen sharply, pharmacies practice questionable billing, and hotspots for noncontrolled substances have developed.

Medicare spending for Part D drugs has more than doubled since 2006, and spending for commonly abused opioids has grown even faster.

Spending for Part D drugs represents the amount that the Government, beneficiaries, and plan sponsors paid to pharmacies for drugs. From 2006 to 2014, spending for Part D drugs increased by 136 percent, from \$51.3 billion to \$121.1 billion. Over the same time, spending for commonly abused opioids grew from \$1.5 billion to \$3.9 billion, an increase of 156 percent. These drugs are narcotics intended to manage pain from surgery, injury, and illness. They can create a euphoric effect, which in turn makes them very vulnerable to abuse.

The increase in spending for commonly abused opioids appears to have been driven by an increase both in the number of beneficiaries receiving these opioids and in the average number of prescriptions per beneficiary. Both of these numbers have increased more rapidly for commonly abused opioids than for all drugs.

More than 1,400 pharmacies had questionable billing for Part D drugs in 2014, raising concerns about fraud and abuse.

When OIG examined pharmacy billing patterns to look for questionable billing that might be an indicator of fraud, we identified 1,432 retail pharmacies that had questionable billing. Together these pharmacies billed \$2.3 billion to Part D in 2014. These pharmacies each billed excessively high amounts for at least one of the five questionable billing measures we reviewed. Although some of this billing may be legitimate, all pharmacies that bill extremely high amounts warrant further scrutiny. Examples of measures and associated questionable billing in 2014 are described below.

- A total of 468 pharmacies billed for commonly abused opioids in an extremely high percentage of their prescriptions. This may indicate that a pharmacy is billing for medically unnecessary drugs that may be used inappropriately or diverted and resold for a profit. Each of the pharmacies we identified billed for commonly abused opioids in at least 17 percent of its Part D prescriptions—nearly three times the national average.
- A total of 216 pharmacies billed for beneficiaries who had an unusually high number of prescribers for commonly abused opioids. This may indicate that the beneficiaries have been “doctor shopping” for the purpose of inappropriately obtaining prescriptions. These pharmacies billed for beneficiaries who, on average, had at least four prescribers for commonly abused opioids. In comparison, the national average was two prescribers per beneficiary for these drugs.
- A total of 314 pharmacies billed for a high number of different types of drugs, per beneficiary, which may indicate that a pharmacy is billing for drugs that were not provided or that were provided, but were medically unnecessary. Each of these pharmacies billed, on average, for more than 12 different types of drugs for each beneficiary in 2014. This was double the national average.

Geographic hotspots for certain drugs point to possible fraud and abuse.

OIG also identified a number of metropolitan areas where average Medicare payments per beneficiary for certain drugs was significantly higher than the average payments nationwide. We focused this analysis on noncontrolled substances because fraud related to these drugs is becoming more common and can present a substantial financial loss to Medicare and pose the danger of patients taking improperly prescribed medications. Although medical need and prescriber practices may vary across different areas of the country, the patterns in these hotspots warrant further scrutiny, as they may indicate fraud and abuse. Selected hotspots include:

- In the San Juan area in Puerto Rico, the billing for diclofenac potassium, a generic anti-inflammatory used for conditions such as rheumatoid arthritis and osteoarthritis, was 31

times higher than the national average. Almost one-third of all Medicare spending for diclofenac potassium was in this one hotspot.

- In the New York area, billing for Solaraze, a brand-name topical ointment used to treat a skin condition in which lesions form as a result of sun damage, were almost nine times the national average. Half of all Part D spending for this drug, for which there is a less expensive generic equivalent, was in this one hotspot.
- In the McAllen area in Texas, 17 percent (more than four times the national average) of beneficiaries received the prescription version of Nexium, used to treat conditions such as gastroesophageal reflux disease. Medicare paid \$20 million for Nexium in this hotspot, even though there is an over-the-counter version available.

These billing patterns raise questions about whether the drugs were medically necessary or were even provided to beneficiaries in the first place. Also, because some of the drugs are available as generics or over the counter, there are questions about whether pharmacies are billing for the higher priced brand-name drug while providing a less expensive drug.

CHANGES CMS CAN MAKE TO PROTECT THE INTEGRITY OF THE MEDICARE PART D PROGRAM

Since Part D went into effect, OIG has raised concerns about oversight and made a number of recommendations to CMS to better safeguard the program and protect beneficiaries. CMS has made some progress. However, CMS, its National Benefit Integrity Medicare Drug Integrity Contractor (MEDIC), and Part D plan sponsors all need to do more to protect the Medicare Part D Program. OIG recommendations center around two themes: (1) leveraging Part D data to identify vulnerabilities and (2) employing additional tools to enhance the oversight of the Part D Program. Our Part D Portfolio, which we have submitted for the record, goes into each of the unimplemented recommendations in detail.

CMS Needs To Do More To Leverage Part D Data To Identify Vulnerabilities

The availability and proactive use of data are essential to identify and address program vulnerabilities, identify providers with questionable billing, and meaningfully target program integrity resources to the areas of greatest vulnerability. A program as expansive as Part D requires the sophisticated use of data to maintain the visibility and vigilance necessary to uncover, address, and prevent fraud. CMS has taken steps to improve data coordination among the key players tasked with safeguarding Part D. Specifically, CMS has begun sharing plan sponsors' voluntarily reported fraud data with the MEDIC. In addition, CMS and the MEDIC developed a Pharmacy Risk Assessment tool and distributed it to plan sponsors to use in conducting additional analysis. However, much remains to be done. For example:

Increased use of data should include collecting and analyzing data necessary to hold plan sponsors accountable. Plan sponsors are the private insurance companies responsible for administering the program and the program's first line of defense against fraud and abuse. However, CMS does not require plan sponsors to report the number of instances of potential fraud, waste, and abuse they identify, nor the actions they took to address them. In lieu of a requirement, CMS established a mechanism for plan sponsors to voluntarily report data to CMS. But less than half of Part D plan sponsors did so between 2010 and 2012. Without this information from plan sponsors, it is impossible for CMS to review the effectiveness of plan sponsors' fraud detection programs.

Increased use of data should also involve making better use of the data already collected. We recommend that CMS and plan sponsors monitor beneficiary utilization for a wider range of drugs susceptible to abuse than they currently do. In particular, we recommend expanding sponsors' and CMS's drug utilization review to cover certain noncontrolled substances, such as HIV and antipsychotic medications.

Additionally, while the MEDIC is CMS's key program integrity contractor for Part D and is required to investigate potential fraud and abuse, OIG found that the MEDIC used proactive data analysis to initiate only a small percentage of investigations and case referrals, and instead relied on external sources to identify most incidents of potential fraud and abuse. Although the percentage of the MEDIC's investigations initiated from proactive analysis has increased over the years, it still remains around 10 percent—a rather small percentage.

CMS Needs To Employ Additional Measures to Enhance Its Monitoring of Fraud, Waste, and Abuse In Part D

Each entity involved in Part D has a role in detecting and preventing fraud, waste, and abuse. Plan sponsors have the primary responsibility for reviewing and paying claims. As such, they must have adequate controls in place to prevent improper payments. CMS, in turn, must exercise proper oversight of both the plan sponsors and the MEDIC to ensure that those entities are working to reduce the program's vulnerability to fraud, waste, and abuse.

Recently, CMS has implemented measures to bolster its monitoring and oversight of providers in Part D. For example, CMS provided the MEDIC with the authority to request and collect information that it needs to investigate potential fraud directly from pharmacies and other entities. CMS now requires plan sponsors to verify that prescribers have the authority to prescribe drugs and that claims contain valid prescriber identifiers. CMS recouped some payments made after beneficiaries' deaths. It also provided data to plan sponsors to help them identify claims associated with excluded providers. In addition, CMS expanded its guidance regarding the proper billing of Schedule II drugs, and plan sponsors

have reported strengthening their controls for these drugs. But, again, more remains to be done.

CMS, the MEDIC, and plan sponsors need to strengthen program oversight by employing additional tools. Our work has shown that the current approach to oversight is not sufficient to protect Part D. There are four key areas where we recommend further action.

Strengthen controls to prevent payments for drugs not covered by Part D such as payments to providers who are excluded from Federal health care programs. OIG has found that plan sponsors do not have adequate controls to prevent improper payments. OIG has found that plan sponsors' processes have sometimes compromised their ability to detect, correct, and prevent fraud, waste, and abuse. CMS has not exercised sufficient oversight of plan sponsors to prevent improper payments, such as payment for drugs that are not covered by Part D. For instance, OIG has found that appropriate controls were not in place to prevent Part D payments for drugs prescribed by providers excluded from Federal health care programs. It is important that claims for drugs prescribed by excluded providers be denied to protect beneficiaries from inappropriate or even harmful services.

Conduct a more robust oversight of plan sponsors' compliance programs. Plan sponsor compliance programs provide the roadmap for sponsors' efforts to prevent and detect fraud, waste, and abuse. They outline the protections the plan sponsor will put in place. However, OIG has identified weaknesses in CMS's oversight of plan sponsors' implementation of compliance programs. Rectifying these weaknesses would lead to stronger and more consistent prevention measures to avoid fraud, waste, and abuse at the very beginning of the Part D payment process. For these reasons, CMS should provide additional oversight of plan sponsors to ensure effective implementation of compliance programs, one of the primary tools for Part D program integrity.

CMS needs a mechanism that would allow it to recover inappropriate payments in cases that have been declined by law enforcement agencies. The MEDIC currently does not have administrative authority to recommend recoupment of payments associated with inappropriate services. When law enforcement agencies do not accept MEDIC cases for further action, the MEDIC simply closes these cases because there are no established procedures to recommend recoupment of inappropriate payments.

The law should be changed to more effectively deal with beneficiaries who may be abusing the program or inflicting harm on themselves by overutilizing drugs. OIG investigations have found that Part D beneficiaries can be both victims and perpetrators of fraud. Beneficiaries can be harmed by overprescribing. On the other hand, some of the fraud trends prevalent in Part D involve beneficiaries who act as complicit patients. For example, in one investigation, the complicit beneficiary received unnecessary prescriptions, filled them at various pharmacies, and sold the pills to drug-trafficking organizations. This could be addressed by *restricting* beneficiaries to a limited number of pharmacists or prescribers when

warranted. This is commonly referred to as “lock-in” and has been successfully implemented by State Medicaid programs. However, CMS has stated that it would require legislative authority to implement these restrictions.

CONCLUSION

As the agency charged with administering and overseeing Part D, CMS is responsible for improving the program’s effectiveness and protecting its beneficiaries. To protect the integrity of Part D, CMS should take action on OIG’s unimplemented recommendations. OIG believes that CMS should employ all the tools at its disposal. CMS needs to more effectively collect and analyze program data to proactively identify and resolve program vulnerabilities and prevent fraud, waste, and abuse before it occurs. CMS also needs to implement a robust oversight plan designed to ensure proper payments, prevent fraud, and protect beneficiaries.

As the Part D program continues to evolve and new fraud schemes emerge, OIG will continue to investigate fraud and offer recommendations to improve oversight and establish new methods for early detection and prevention of fraud, waste, and abuse.

Thank you again for inviting me to speak with the committee today to share the results of OIG’s audits, evaluations, and investigations on Part D. I would be happy to answer any questions the committee may have.

Mr. MURPHY. Thank you. I will now recognize myself for 5 minutes as we go through this.

First of all, we know that prescription drugs and medications can heal, they can reduce symptoms, they can keep people out of hospitals. Dr. Agrawal, does CMS have any kind of report that really takes an accounting as the prices have gone up in Medicare Part D? Has there been any corresponding decrease in hospitalizations or doctor visits? Is there any report of that type out there?

Dr. AGRAWAL. Chairman, that is a good question. I am not aware of a report along those lines. I may have just not seen it, so I am happy to take that question back.

Mr. MURPHY. Thank you. I wish you would.

Ms. Maxwell, you pointed out in your testimony about nine unimplemented recommendations that the OIG identified. So as she stated that, Doctor—and some of those go all the way back to 2006. Does CMS agree with the recommendations made by OIG?

Dr. AGRAWAL. I think we do agree with the recommendations. I think we have expressed that in writing to those reports. You know, what I would emphasize is, these are all recommendations that we are working to make progress on. I think it is very fair to say, you know, that we need to continue to work on it, need to get to completion. These are often multifaceted recommendations that require, you know, multiple levels of implementation.

Mr. MURPHY. But you recognize some of these go back to 2006, so I am sure many members are going to key in on trying to get some commitments from you to get that done.

But let me focus on one of those. The OIG recommended that CMS exclude schedule II refills when calculating final payments to plan sponsors at the end of each year. So what action has CMS taken to implement that recommendation? Ms. Maxwell, can you answer that first? Do you know if they have taken action on that?

Ms. MAXWELL. Absolutely. It is my understanding—and this is one of the recommendations in which CMS did not concur. Seven of the nine initially CMS did concur with. There are two they didn't. This is one of them. It is my understanding that CMS is concerned about the data that is available and the data does not make it obvious what is a partial refill versus what is an illegal refill, and that they have instituted actions to make it more clear in the data. Our position is, once the data is clear, then you have the opportunity to put in an edit, and we would continue to recommend that they do put in an edit to stop those illegal refills.

Mr. MURPHY. Dr. Agrawal, what is your plan of action here?

Dr. AGRAWAL. Yes, I think Ms. Maxwell has characterized that correctly. So our concern is that the data is not completely accurate at this point. Early refills of schedule II drugs are illegal. We of course don't support early refills of those drugs. However, partial fills, particularly for beneficiaries that may be in long-term-care facilities, are totally legitimate and may actually help to address pain and other issues that they have. So what we are doing is working with plan sponsors to clarify coding requirements so that we can differentiate the legitimate payments from the illegitimate payments and then would be seeking to make the kind of change that is being described.

Mr. MURPHY. And as part of that, hopefully you will also be going after people who have made the wrong claims and getting that money returned.

On page 3 of your testimony, Doctor, you had mentioned the President's budget proposes to provide the Secretary with new authorities to suspend coverage and payment for drugs prescribed by providers who have been engaged in misprescribing to suspend coverage and payment for Part D drugs when those prescriptions present an imminent risk to patients and require additional information on certain Part D prescriptions such as diagnosis instant codes and conditional coverage. Do you have any estimate that this will actually save money in terms of reducing some of the fraud and abuse to implement those recommendations?

Dr. AGRAWAL. Yes, I think these kinds of recommendations really go at the heart of prevention, moving away from the pay-and-chase model that others have commented on. We did promulgate policy, as you know, last year requiring enrollment to prescribers and also with that implementing the ability to revoke providers for abusive prescribing. I think all of those things really do take a very strong step towards prevention, just as we have done in other parts of the program and have been shown to be effective.

Mr. MURPHY. I was hoping that was something you can give us some numbers on in terms of what you estimate that would be savings to Medicare Part D. That would be important to us if we implement those.

Let me mention something else here. This is on Medicaid but it is important, because a report just came out in March issued by the HHS Office of Inspector General and found that 92 percent of Medicaid enrolled children who are prescribed antipsychotic medications lacked "medically accepted pediatric indications" that would warrant such prescriptions. There were instances there of very young children being prescribed antipsychotics, 4-year-olds. It was a very disturbing and alarming report. That 92 percent number of not medically indicated was absolutely astounding. So given that, and I don't expect you to know this today, but if you do know, I would like to know what steps CMS is taking to root out the providers who are prescribing children powerful psychotropic medications when it isn't medically necessary. Would you make sure you get back to us on that?

Dr. AGRAWAL. Absolutely.

Mr. MURPHY. And finally, the OIG has recommended that CMS implement an edit to reject prescriptions written by excluded providers. So Ms. Maxwell, what actions has CMS taken to implement that recommendation of those who aren't supposed to be prescribing at all?

Ms. MAXWELL. It is my understanding that the sponsors are required to be monitoring excluded providers and making sure that the payments don't go to them. However, when we did look, we did find that CMS did accept PDE records from the sponsors that included excluded providers. There was about 15 million in gross payments over a 3-year period. So again, we continue to appreciate the steps that have been taken but there's obviously need for further steps and stronger payment controls be put into place.

Mr. MURPHY. OK. I would like to follow up, but I am out of time so I will now turn to Ms. DeGette for 5 minutes.

Ms. DEGETTE. Let me sort of extend that previous line of questioning, which is, we are talking about the OIG report on Medicare Part D integrity and the report notes "CMS relies on plan sponsors to be the first line of defense against fraud, waste, and abuse in Part D." I am wondering if both of you can each comment on the role that plan sponsors play in this first line of defense against waste, fraud, and abuse. I am wondering what tools they use and what can be done. Dr. Agrawal?

Dr. AGRAWAL. Sure. Thank you. I do think, you know, the role of Part D plan sponsors is extremely important since they are paying claims or PDE records directly.

Let me just address maybe the prior point about providers first.

Ms. DEGETTE. Sure.

Dr. AGRAWAL. You know, I think it is absolutely indefensible for a Part D plan sponsor to pay the prescription of an excluded provider. Now, we have implemented edits behind those plan sponsors to indicate when they have done that so they can make the appropriate recoveries on their end. I also think prescriber enrollment and the screening requirements that I mentioned earlier will go a long way, because it will move those edits from after the PDE record to the point of sale when we have all 400,000 prescribers enrolled in the program.

So we can clearly buttress Part D plan sponsors but their role is absolutely vital. I think they need to be on top of the data. We share a lot of data with them so that they are aware of who the outlier prescribers and pharmacies and their networks are. They also have the ability to implement drug utilization reviews and other kinds of programs including case management to stem both abusive prescribing as well as abusive utilization.

Ms. DEGETTE. So let us talk about that data for a minute because they are not required to report the data on potential fraud and abuse, and in fact, the percentage of plan sponsors that voluntarily report this has declined over the last few years down from 40 percent in 2010 to 35 percent in 2012. Do you have any more recent data about the trends on this?

Dr. AGRAWAL. I don't think we have more recent data that I can share today. However, this is an area that we have been working to make progress as well. So as I mentioned, we give data to the plan sponsors on a quarterly basis, and just this year implemented a system for them to be able to report back to us what actions they took as a result. I think that system, which allows the data to be reported, and then for it to be searchable and analyzable has been an important step moving us towards better reporting.

Ms. DEGETTE. What is your view on this, Ms. Maxwell?

Ms. MAXWELL. It is absolutely true that, as I said in my oral, that the sponsors are the first line of defense. They administer the program and they are the ones that are paying the pharmacies but CMS, as I said, is the second line of defense, and if things do slip through the processes and edits they have in place, it is incumbent upon CMS to have the second line of defense to prevent that from happening. That prevents the Federal Government from actually reimbursing the mistakes the sponsors might be making.

Ms. DEGETTE. And do you think CMS is doing enough to encourage that?

Ms. MAXWELL. I think CMS has made significant strides in response to many of our recommendations, and of course, we outline nine in the report that we believe are important to be included in their ongoing effort to improve program integrity.

Ms. DEGETTE. And what about the plan sponsors' fraud detection programs themselves? Do you think that the plan sponsors are doing enough or can they be beefing up that over time?

Ms. MAXWELL. If we had the data about the fraud and abuse incidents that they are detecting as well as the data about how they are responding, we would be able to answer that question with more authority. We really don't have the visibility that we think is necessary to hold them accountable.

Ms. DEGETTE. Is that something, Dr. Agrawal, you think you could provide?

Dr. AGRAWAL. Well, as I mentioned, we are getting some data from plan sponsors, and in particular, we are focused on where we give them a clear lead such as an outlier pharmacy or an outlier prescriber, what are they doing to investigate that lead downstream and then take the relevant actions. What we have found is certain plan sponsors are actually good at following up. So we have been able to see hundreds of pharmacies be excluded from networks because of the leads we give them. We also conduct compliance reviews of plan sponsors to make sure that program integrity processes are a robust part of their operations. Again, some plan sponsors I think do quite well there and others have opportunities for improvement.

Ms. DEGETTE. Well, this is an area where it seems like there could be a lot of problems, and OIG has recommended making it mandatory that they report potential fraud and abuse. I am wondering, first, Ms. Maxwell, could you comment on that recommendation?

Ms. MAXWELL. Absolutely. As you have pointed out, given the current state of affairs that it is not currently voluntary, we don't have full compliance.

Ms. DEGETTE. Right.

Ms. MAXWELL. And so we believe we will not have full compliance unless it is mandated, and without the comprehensive reporting of that data, we can't look across the entire program and see—

Ms. DEGETTE. Dr. Agrawal, what is your agency's response to that?

Dr. AGRAWAL. Yes, I think we can essentially agree with that, you know, the notion a lot. I think the question for us is, what kind of reporting is the most beneficial for other plan sponsors and the agency, and so implementing something like the PLATO system, giving them leads, and then getting results from those leads is a step towards answering exactly that question of what kind of information return is useful to the agency and would be useful to other plan sponsors. I think as we get more information and get better understanding of the utility, we will be able to require more of plan sponsors.

Ms. DEGETTE. I am sure we have more questions around that line too. Thank you.

Mr. MURPHY. Thank you. I now recognize the gentlelady from Tennessee, Mrs. Blackburn, for 5 minutes.

Mrs. BLACKBURN. Thank you, Mr. Chairman, and I am going to follow right along with what Ms. DeGette was saying.

It is troublesome when we hear—and Ms. Maxwell, of course, you all have done so much work on this—with the voluntary nature of the reporting, and you have recommended that they make it mandatory, and so Dr. Agrawal, what are you doing to beef up the compliance? You can say well, we have PLATO, well, we have this, you know, but what are you doing to enforce this? How do the people that work at CMS understand this is an imperative, you have got to do this? I mean, how do you communicate that?

Dr. AGRAWAL. I think we take all of OIG's recommendations as important contributions, as imperatives. We do work to implement—

Mrs. BLACKBURN. Whoa, whoa, whoa. Wait a minute. They are not contributions. They have pointed out to you—let us not even start down that road. It is not a contribution. It is, you are doing this wrong, you are wasting money, the fraud has been identified. Let us just say it like this. They have got nine recommendations on the table. Do you agree with those recommendations, yes or no?

Dr. AGRAWAL. I think we have indicated that we largely agree with those recommendations, yes.

Mrs. BLACKBURN. That is not the question that I asked. Yes or no?

Dr. AGRAWAL. Well, I think Ms. Maxwell has pointed out that the agency has agreed with seven of the nine recommendations.

Mrs. BLACKBURN. OK. Well, the problem is, what are you doing then to take an action, and what is your timeline? You know, you seem to come here and punt, and we have got another report that came out this morning. You are saying oh—and oh, by the way, it is only 2 months late. You are 2 months late with your report. People in the private sector that deliver a report 2 months late generally are, you know—they have other problems.

OK. So let us look at this. You are saying you have recovered \$454 million and that your Fraud Prevention System is returning a 10:1 ratio on this investment, and you are very proud of that, but you have got a lot of other waste that is out there, so I want to know from you specifically how are you enforcing the recommendations and what is your timeline for bringing your agency's work into compliance on a program that is really important to our Nation's seniors, and that is not that difficult a question. Now, getting the work done obviously that is a little bit harder for you, but we want to know specifics on your enforcement and specifics on your timeline of meeting this.

Dr. AGRAWAL. First, Congresswoman, let me just say on the Fraud Prevention System report that those numbers have been certified by the OIG itself, and this was a report that we worked on in conjunction with them throughout the timeline—

Mrs. BLACKBURN. I am fully aware of that.

Dr. AGRAWAL. So I think the 10:1 ROI is positive, obviously, a good development for the system. As to your questions about the

various recommendations, I am happy to take that back and we can give you responses for each recommendation, what we have done to implement them. I think on every recommendation we have worked to make progress to implement various systems and changes towards finally completing that recommendation, but these recommendations do take time to implement.

Mrs. BLACKBURN. OK. You said you had the authority to do the job. We know that you have the money and the personnel. Why does the job not get done? Is it not a priority?

Dr. AGRAWAL. This is an absolute priority. We have many staff focused every day on the integrity of the Medicare program—

Ms. BLACKBURN. Do they understand that they are expected to meet a timeline? Do you all have a timeline? You still haven't spoken to the timeline.

Dr. AGRAWAL. It think it depends on which recommendation you are referencing.

Mrs. BLACKBURN. No, no, all of them. You have got—you can't pick and choose on this. You have got a list of recommendations. You have had waste, fraud, and abuse identified. You know you have got problems with the opioids. You know that voluntary reporting gets you part of the way but it doesn't get you all the way, that this needs to be made mandatory. So as to the leader, what are you doing to make certain that there is a set timeline? When is the timeline? Is it the next report? Is it the next hearing? Is it the end of the year?

Dr. AGRAWAL. Yes, so let me give you an example, Congresswoman. So we have been very specific when it comes to something like prescriber enrollment, which will actually go towards resolving at least two of the recommendations I believe that OIG has put forward around excluded providers or other kind of invalid prescribers. We have stated—you know, we promulgated the necessary rulemaking last year. We are now working with Part D plan sponsors to get these prescribers enrolled so that we don't cause an interruption in legitimate access to services, and we have said that that enrollment requirement needs to be met by January 2016 between both the plan sponsors and CMS working collaboratively together. We will then implement point-of-sale edits behind that enrollment in June of 2016, which I think will take a significant step towards really eliminating excluded prescribing or other invalid prescribing—

Mrs. BLACKBURN. So basically you are giving yourself a year to come into compliance with something that you know has been a problem.

Dr. AGRAWAL. Well, I think that that—

Mrs. BLACKBURN. I yield back my time.

Mr. MURPHY. I now recognize Mr. Pallone for 5 minutes. We can let him answer? I will let him answer. Go ahead. You can answer. Let me do that first.

Dr. AGRAWAL. Thank you. I think it highlights some of the technical challenges in actually getting this work done. So we have to be very careful to actually enroll 400,000 prescribers so that we do not interfere in legitimate access to services that the Part D program provides beneficiaries. We balance that against the need to do this quickly and effectively to stem the various weaknesses and

issues that the OIG has correctly pointed out. This is a balance we work to achieve every day. So yes, it takes time. It takes time for prescribers to get up to speed on the requirements and get enrolled. It takes time for our Part D plan sponsors to initiate the necessary actions on their part and get the point-of-sale edits in place as well.

Mr. MURPHY. Thank you.

Mr. PALLONE.

Mr. PALLONE. Thank you. I believe that both of our witnesses here today have studied a growing phenomenon that is deeply concerning, and that is the overprescribing and/or the overuse of opioids in Medicare Part D. This is an issue that we have all worked on for many years in response to OIG's earlier work on this topic.

I introduced the Medicare Prescription Drug Integrity Act of 2013. Since that time, OIG has repeatedly recommended that CMS seek statutory authority to restrict certain beneficiaries to a limited number of pharmacies or prescribers when warranted by excessive or questionable billing patterns. This practice, commonly referred to as lock-in, I mentioned in my opening statement has been successful implemented in the private insurance market and some State Medicaid programs.

In the 21st Century Cures legislation that the House overwhelmingly passed on Friday, there is a provision that would allow Medicare Part D plan sponsors to use these types of drug management programs to curb potentially harmful use of opioids and other controlled substances, and that provision as agreed to in the legislation strikes the right balance between protecting beneficiary choice and access while also improving continuity of care by ensuring that those high-risk patients obtain and fulfill prescriptions for controlled substances only from designated providers, and I think that is a big step in the right direction.

So let me ask some questions. Ms. Maxwell, can you summarize OIG's findings that have led the agency to repeatedly recommend that Congress gives CMS authority to allow Part D plan sponsors to create these so-called lock-in programs?

Ms. MAXWELL. Absolutely. As our current data shows, the rate of increase of use of opioids within Part D has far outpaced the general increase in drugs. In fact, it has grown 156 percent since the inception of the program. We also see, as I mentioned, the pharmacy fraud where we see pharmacies allowing for opioids to flow into the streets and be diverted. This poses not only a patient harm issue for the beneficiaries but also is a public health issue for some of those things that flow into the streets end up back on pharmacy shelves, which affects all of us. This is a significant issue, and we believe the lock-in would be a significant move forward in protecting the program beneficiaries from patient harm as well as the program from significant financial loss.

Mr. PALLONE. Thank you.

Dr. Agrawal, do you believe that if a pharmacy lock-in provision in 21st Century Cures was signed into law, CMS would have a much-needed tool to address opioid abuse and overprescribing in Part D, and have these types of lock-in programs been successful in curbing opioid abuse and other programs?

Dr. AGRAWAL. Yes, I would certainly agree with Ms. Maxwell that we have seen beneficiaries that are really at safety risk from the levels of utilization of their opioid medications. We have been supportive of this kind of legislative change to provide a lock-in approach. It is part of the President's budget. I do believe that it would have impact as it has, as you have already pointed out, in both the private sector as well as in various Medicaid programs.

Mr. PALLONE. OK. I want to switch to that report that Mrs. Blackburn mentioned, the Fraud Prevention System report that the agency released this morning. The FPS uses predictive and analytics to detect troublesome billing problems and provide it to the Medicare program, and after 3 years of operation, CMS today reported that the system identified or prevented \$820 million in inappropriate payments in the program's first 3 years.

So Dr. Agrawal, first of all, I want to commend you on your work on the FPS. In its third year, how has the program changed and matured? And let me throw in the second question too because of time. Does CMS plan to expand the program to Part C and Part D in the near future, and what additional plans does the agency have to expand the FPS to additional fraud detection activities?

Dr. AGRAWAL. Sure. Thank you for the question. Currently, the FPS streams all Medicare A, B, and DME claims, so about 4 1/2 million claims per day. I think what we have seen over the last 3 years in terms of evolution of the program is more models being implemented, more sophisticated models being implemented that not only look at outlier behavior but are truly predictive models based on the input of our own investigative field staff as well as the input of law enforcement, both OIG and DOJ, based on prior kind of patterns of fraud and abuse that they have noted. So that is one really big change is on sort of the technology side and just improving the modeling.

The second is making sure that these leads are actually being followed. So this was almost a cultural change or just a contractor accountability change to make sure that our Program Integrity Contractors took these leads seriously, they formed a substantive, substantial part of their workload, and they were driving towards real administrative outcomes as quickly as possible.

I think what we will continue to do with this program is continue to leverage the technology to implement new approaches like edits so that claims can be stopped from being paid, you know, before they are actually ever paid. We have been doing some of that already in the first 3 years, and we are looking to expand that capability substantially going forward. I think also the maturing of the modeling will facilitate this process.

To your question about other data sources, we have started to fold in Part D PDE records and we will be looking to do that more. I think in Part C, we still have the challenge of getting accurate encounter data from plan sponsors, so we are still working with the relevant parts of CMS and plan sponsors to help improve that encounter data.

Mr. PALLONE. Thank you.

Thank you, Mr. Chairman.

Mr. MURPHY. Thank you.

I now recognize Mr. Barton for 5 minutes.

Mr. BARTON. Thank you, Mr. Chairman.

I guess the first thing we ought to do is thank HHS and the Inspector General for conducting the investigation and actually beginning to try to correct the problem and at least identifying some of the bad guys. That is a good start.

My first question I guess would be to Dr. Agrawal. Is that correct?

Dr. AGRAWAL. You nailed it.

Mr. BARTON. Well, how about that? Just a lucky guess.

How in the world can somebody be on Medicare Part D if they are not enrolled in Medicare? If I heard correctly, you said some people are actually getting the benefit but they are not in the program. I don't understand that.

Dr. AGRAWAL. No, sir, it is not on the beneficiary side of the equation. It is the prescriber, the physician or advanced-practice nurse, for example, who actually sends a prescription in, hands it to a patient. Currently or prior to last year, there was no specific enrollment requirement for the provider. There is now, so going forward, all prescribers are going to have to come into the program, be subject to the same screening standards as in the rest of Medicare.

Mr. BARTON. OK, but prior to this year, a provider could reject Medicare patients but prescribe Medicare Part D prescriptions?

Dr. AGRAWAL. Correct. It is been a huge program integrity focus to bring this up to the rest of the level—to the level of the rest of the program.

Mr. BARTON. But that is no longer a problem? That is one loophole that has been closed?

Dr. AGRAWAL. We are in the process of closing it as we—

Mr. BARTON. In the process—

Dr. AGRAWAL [continuing]. Get through enrollment. As I mentioned, we have to enroll 400,000 prescribers by January.

Mr. BARTON. OK. And if they have a doctor that is not in the program, you just send a letter to the patients that that is not a valid prescriber. Is that correct?

Dr. AGRAWAL. Yes. So the balance with beneficiary access to medications is important. What we have done is created essentially a transition period. So if a beneficiary takes a prescription to a pharmacy from a prescriber who is not enrolled, they will get that information but they will also get the medication so that there is no interruption in their therapy. They will not get it the second time. By that time we would have expected the provider to either be enrolled or for the beneficiary to go to a different provider.

Mr. BARTON. OK. Now I am going to switch to Ms. Maxwell.

One of the recommendations that hasn't been acted on but apparently you all are beginning—the program is beginning to act upon is this idea of mandatory reporting from the plans. I am not a big fan of mandatory anything except people paying the taxes. I guess that ought to be mandatory. Why not go the other way? Why not create—I heard that—voluntary compliance, but you go to jail if you don't voluntarily comply. All right. A minor point.

Why not go the other way and provide an incentive to the plan that you don't have to report, but if you do and it really is fraudulent and we recover some of the program funds, we will give you

a percentage of the monies that are fraudulently—have been fraudulently paid and then recovered? Why not create an incentive program? That works for me, and I think most Republicans would prefer it. Now, I may be wrong but I would rather have an incentive to do it than a mandate they have to do it.

Ms. MAXWELL. You know, the heart of our recommendation is to have the visibility to oversight, so as long as we have the data and the visibility to what the plan sponsors were doing to protect the program, that is ultimately what we are after.

Mr. BARTON. Congressman Gingrich when he was Speaker put in or at least requested that this committee put in a program where you could create a hotline that people could call in to, and if it turned out that—and this wasn't just for Medicare, this was before Medicare Part D obviously—but if there was fraud involved and somebody reported it and it was proven and stopped, the person who reported it got some sort of a bonus, and that would be another idea to think about.

I will go back to the doctor. This is my last question. You may have to get back to me on this. Just at the basic level, I would like to know where you think the primary cause of the fraud is. Is it from the patient's standpoint? You have got phantom patients perhaps. Is it from the pharmacy standpoint? Is it from a plan who is overbilling even though they don't have patients? Or is it possible it could even be in the Government itself where they work in conjunction with the plan to create fraud? Do you have any data on that?

Dr. AGRAWAL. I think what we see is that overutilization in Part D is multifaceted. It occurs at patient, prescriber, the pharmacy, which is why the response to it—and I think the OIG has pointed this out as well—the response to has to be multifaceted. The program has to try to address all of the different areas that fraud or abuse could be occurring.

Mr. BARTON. If you identify the most prevailing area, then you put most of your assets there and you will have a better chance to get a greater return on your investigations.

With that, Mr. Chairman, I yield back.

Mr. MURPHY. Thank you. The gentleman yields back.

I now recognize the gentleman from Massachusetts, Mr. Kennedy, for 5 minutes.

Mr. KENNEDY. Mr. Chairman, thank you, and thank you for holding an important hearing. Thank you to our witnesses once again for coming back.

I am going to touch on some—try to flesh out a little bit some of what my colleagues have already touched on for both of you. Obviously Medicare Part D is a large and important program, serving millions of seniors across the country and a good deal of them in my district. Given the scope and the number of transactions involved, proactive data analysis is an essential tool to focus on fraud detection and enforcement efforts.

The OIG Data Brief does just that, highlighting some notable outliers when it comes to pharmacy billing. In particular, the suspicious prescriptions for opioids are especially troubling, given the nationwide epidemic that we have heard about at previous hearings and some of my colleagues have already touched on.

So according to the Data Brief, “spending for commonly abused opioids grew at a faster rate than spending for all drugs.” That was on page 3, I believe.

So Dr. Agrawal, it is my understanding that the initial comparison with 2011 data shows that there has been a substantial reduction in the number of acetaminophen and opioid overutilizers. I was hoping you can try to flesh out a little bit more about CMS’ measures to prevent the overutilization of prescription medications within the Part D program.

Dr. AGRAWAL. Sure. So I think where there are—so again, multiple facets to the issue where there is beneficiary overutilization where, you know, we can identify beneficiaries that have exceeded what we would consider kind of standardly accepted safety thresholds. We share that information with Part D plan sponsors through our Overutilization Management System. That gives them the specific beneficiaries that they can then implement I think more proactive drug utilization reviews around including case management. What we have seen when we focus on things like schedule II drugs is a 30 percent decline in the prevalence of those beneficiaries, which shows that both the data sharing and the actions being taken on the part of the plan sponsors is having an impact, and we continue to provide that information on a quarterly basis so that plan sponsors can continue that work.

Mr. KENNEDY. Thank you.

And Ms. Maxwell, you touched on in your opening statement one of the pieces that were highlighted in the report of a Detroit-area pharmacy that billed for commonly used opioids for 93 percent of its beneficiaries. It amounted to 58 percent of all of its Part D prescriptions. Can you talk a little bit about OIG’s plan for follow-up in the questionable pharmacy billing 3-year study and tell us a little bit more about the proactive analysis that you ensuring Medicare to take in a broader report?

Ms. MAXWELL. Absolutely. As I mentioned in my opening remarks, when we were proceeding in the takedown, we were already mining the data for new leads. We already have 1,400 retail pharmacies targeted that had questionable Medicare billing. We are actively investigating some portion of those, and we have referred the rest to CMS for investigation. So the Data Brief allows us to see where there are areas for questionable billing and the next step is to investigate and weed out which one of those really represent legitimate business and which are fraud that we need to pursue either with OIG investigations or in conjunction with CMS.

Mr. KENNEDY. And Dr. Agrawal, what’s the—after those are referred over to CMS, what is CMS’ next steps?

Dr. AGRAWAL. Yes, so again, I would agree that these—that the analytical work is a good starting point for further refinement and then also investigative activity. Now, let me just say it is the construct of the program that CMS doesn’t have a direct relationship with pharmacies. That relationship really occurs with Part D plans. Pharmacies don’t enroll or anything like that in the program.

For that reason, we have to work through Part D plan sponsors by giving them better data and, you know, then they take the necessary investigative and other administrative actions. We certainly will utilize the information given to us by the IG so they gave us

about a thousand of the roughly 1,400 pharmacies have been sent over to us, and we have been sharing that, or have shared that already with plan sponsors.

In addition, on a quarterly basis, we do similar work utilizing sort of a greater set of variables to identify high-risk pharmacies and again share that information on a quarterly basis, which has yielded literally hundreds of pharmacies being excluded from plan sponsor networks.

Mr. KENNEDY. Thank you. And then the brief highlights some geographic hotspots as well, some metro areas where average payments for certain drugs are much more than the average nationwide.

Ms. Maxwell, in conducting the analysis, did OIG evaluate patterns for all non-controlled drugs or did you just focus on specific ones?

Ms. MAXWELL. We chose some examples to highlight the potential problems with non-controlled drugs, so there are other drugs that might be of concern that are not highlighted in that Data Brief but the ones we did highlight again like the questionable billing for the pharmacies are worthy of further scrutiny to understand what is happening and stay in front of the evolving healthcare fraud trends.

Mr. KENNEDY. Thank you, and I yield back.

Mr. MURPHY. Dr. Burgess is now recognized for 5 minutes.

Mr. BURGESS. Thank you, Mr. Chairman, and I think you can tell, it is great that we are having the hearing on the integrity of the program as it relates to Part D drugs, particularly with respect to opioids, but you can tell there are a lot of general questions about inappropriate expenditures within the various programs at HHS, and Mr. Chairman, I hope you will take this as perhaps a reason to consider having a general hearing, a general oversight hearing on inappropriate expenditures within the Medicare and Medicaid system.

Mr. Barton talked about previous efforts towards the concept of predictive modeling, and it does seem to me that this is an area where this would be perhaps a particularly useful type of activity. I mean, I got a call at 6 o'clock in the morning a couple of Sundays ago that there had been inappropriate expenditures on my MasterCard. It seems to me that with the amount of data that you all collect on a daily basis, you ought to be able to do a pretty good job of isolating—identifying and isolating and investigating unusual trends and expenditures. Is that not possible?

Dr. AGRAWAL. Dr. Burgess, I agree that it is. We have been—as I mentioned earlier, we are looking to include Part D data to a greater degree in the FPS system implementing new models just around this program as we demonstrated the impact of the FPS.

Mr. BURGESS. It just calls up the question of, you know, the scale of the problem is likely to be much more massive than any recovery that has been affected to date.

I do want to ask a couple of questions, and I realize it is a little bit off topic, but I know, Dr. Agrawal, we have talked about this before. Ms. Maxwell, I apologize, I don't remember whether our offices talked to you directly, but it does affect you also.

We had a hospital in Texas—Dr. Tariq Mahmood—who took \$18 million for the development of an electronic record system and basically just put his medical records down to the basement and let the mice eat them, not computer mice, real furry mice. So what can you all do—I mean, yes, one of the manager has gone to jail, the doctor will have a trial at some point and likely will face jail time through the Department of Justice, but what can you all do to recover that \$18 million that was inappropriately dispensed under the stimulus plan to this hospital chain?

Dr. AGRAWAL. So thank you for the question, and I am aware of the case. I have to tell you, I think it occurred a while back so we—you know, I think the general answer is, we do conduct audits of the EHR payments, incentive payments that we make, and where we find discrepancies, we are able to recover those dollars. This was the case that I know we worked on conjointly with the OIG so I can't tell you if the audit came first or the OIG investigation did. If you are interested in that, perhaps I can take it back. But these audits are meant to address exactly the vulnerability that you are identifying, which is, you know, essentially false statements that you have implemented an EHR, a viable EHR system. We do look at that question.

Mr. BURGESS. And to answer your question, I would be interested, but see, this is the problem and this is what just drives people crazy. We kind of get into this circuitous stuff between agencies, and I think—again, I think we have had this conversation before. I am told it is under investigation. But really, where are we at getting the 18 million bucks that the taxpayer is on the hook for for sending these dollars down to Dr. Mahmood? Does either office have that interest in recovering that money?

Dr. AGRAWAL. Of course we do, and I will happily take that question back, I mean, to specifically address whether the \$18 million has ever been recovered. I don't want to leave you with a false impression about this particular case. This was something that we did work in coordination with the OIG. It wasn't sort of a turf battle or anything like that, you know. My answer is just, I don't know if they identified the issue first and then came to us or vice versa. But we did coordinate across this case.

Mr. BURGESS. I actually think it was my newspaper, the Dallas Morning News, that identified the problem and I brought it to your attention.

But, I mean, again, this is what just drives people crazy. You have a massive inappropriate expenditure of Federal money, and then no one seems to be primarily responsible for going and recovering it, and quite honestly, reporting back to Congress about what the status of that recovery is. In your own statement this morning, Dr. Agrawal, you said well, this was some time ago. Yes, it was some time ago, so we would like the dollars back, please, and I know this individual has—it has been reported that he has got plenty of assets so this is something that you would think with the full force of the Federal Government and Department of Justice we would be able to go and effect that recovery.

Thank you, Mr. Chairman. I will yield back the time, but I do want to follow up with both of you and understand where the status of this recovery is.

Mr. MURPHY. Thank you.

I now recognize Mr. Yarmuth for 5 minutes.

Mr. YARMUTH. Thank you, Mr. Chairman. I appreciate your holding this hearing. I think as has been demonstrated, both sides are very much interested in rooting out all the waste, fraud, and abuse that exists in the Medicare system. Thanks to the witnesses for the work you are doing.

I tend to—I do have a question about that, but before I do that, I want to take this opportunity as I often do to talk about the experience in Kentucky with the Affordable Care Act and the great work that my Governor, Steve Beshear, and his team have done in implementing the expansion of Medicaid and what has meant for our State. We have more than a half-million people who are newly enrolled in Medicaid and in private insurance as a result of the ACA. That is in the range of 4.4 million. We have reduced the uninsured rate by almost 50 percent in Kentucky. In my district alone, the uninsured rate has dropped by 81 percent. Pretty astounding.

More importantly, for those who say that this is economically nonfeasible, the State employed the Deloitte firm to analyze the prospects for Kentucky's economy over the next 6 years under ACA, and they determined that under ACA, Kentucky would experience added economic activity of \$30 billion, the creation of 40,000 new jobs, and I think most importantly, from the taxpayer's perspective, an impact, a positive impact on the State budget of \$819 million. So I think those statistics demonstrate that the ACA can be very, very positive, not just in insuring people, giving them access to quality care but also from an economic perspective.

So we have talked a lot about Medicare Part D and the fraud provisions and your work in those areas. There is a related issue when we talk waste as well, and I wanted to talk about prescription drug costs. One of the things that—when I was part of the Democratic Majority back in 2007, one of the first things we did was to pass a bill to allow Medicare to negotiate with drug providers on cost that was not implemented into law. But I was talking with a physician friend of mine the other day, who has done a lot of work in this area, and he was showing me some really incredible statistics about the difference in cost of certain prescription medicines just in my district, and in some areas, the cost was 60 to 70 percent different from one outlet to another.

So my question is, if there are those kinds of potential savings involved just in terms of going from one drugstore or one grocery store to another, why can't we have some kind of systemic approach to that from CMS? Doctor, do you want to respond to that?

Dr. AGRAWAL. Sure. Thank you for the question.

You know, I can tell from my own practice in the ER, drug costs are an important factor in this whole equation, and the ability of people to be able to pay for the drugs that they get.

I will tell you, as you pointed out, that this is an area where we do not have legislative authority to kind of engage in the negotiation that you are describing.

Mr. YARMUTH. Do you think that it could have a substantial impact on saving money for the taxpayers if you did have legislative authority to do that?

Dr. AGRAWAL. You know, I am not aware. I am sure there is analyses that have been done. I am not aware at this moment what the expected impact would be. Perhaps we could get back to you about that.

Mr. YARMUTH. Well, again, this person has done a lot of work in the area, and he mentioned one drug—I know Ranking Member DeGette talked about saving a billion-plus something in one area—one drug that now is responsible for about \$8 billion worth of sales in the United States every year that actually can be purchased for about 15 percent of that, so you are really talking there about a savings of almost \$7 billion to the system per year if we just had that kind of power to deal with price. So I will just mention that for the record because I think that is something that—as we look at continuing to make Medicare and Medicaid sustainable over time, we are going to have to deal with the issue of the cost of prescription drugs as well as the fraud and abuse side.

So I thank you for your—

Ms. DEGETTE. Will the gentleman yield?

Mr. YARMUTH. I will yield.

Ms. DEGETTE. So the CBO estimates that allowing CMS to negotiate Part D prescription drugs would save \$155 billion over the next 10 years.

Mr. YARMUTH. That is real money.

I yield back, Mr. Chairman.

Mr. MURPHY. And obviously there is more to it than that, and we will continue that discussion. Thank you.

I now recognized Dr. Bucshon for 5 minutes.

Mr. BUCSHON. Thank you, Mr. Chairman.

I was a surgeon before, so I am intimately familiar with the situation, and the bottom line, it seems to me that, you know, nobody out there is defrauding the Government over Lasix or Hyzaar to a large extent. I mean, in my view, we are talking about narcotics. We are talking about a funding stream from the Federal Government that is helping to facilitate the use of narcotics in our country. I mean, that is not the only issue but that is a huge part of it. Without the funding stream, the problem goes away.

And so there are multiple funding streams, and people that abuse narcotics, people that sell narcotics, when they find an avenue to get that paid for in some way, they will take it, and so my point is, there are a lot of other issues other than just payment that this subcommittee has been trying to address, the interconnectability amongst EMRs including those at pharmacies, at the State level, at the Federal level is critical so that we know who is prescribing these medications better than we know today. We know who is using these medications better than we know today. And it is going to take a multiagency approach at the Federal level to address this problem. The payment is only a piece of the pie, right? Payment is a big part of it.

We had a meeting of the Doctors Caucus this morning with the Surgeon General of the United States, a very impressive physician who we talked with him about trying to address this and using his national stage that he potentially has to address this problem. I have worked with—tried to work with the FDA, with the States, with physician organizations and many others. So this is a problem

we are going to have to tackle, and I want to thank this subcommittee and the chairman for bringing that—multiple hearings on that.

So the question I have, Dr. Agrawal, is, how much communication with the other agencies do you have, and is there the development of a plan that is coming together maybe to address this problem knowing that really the big problem why you are being defrauded in Medicare Part D is because of the narcotics. I mean, that is the biggest problem. We all know it.

Dr. AGRAWAL. Thank you for the question. So I would highlight a few things. First, the Secretary of HHS has identified prescription drug abuse as a major priority for the Department, and there is a sort of three-part strategic approach to addressing this issue that the Department has taken on inclusive of all of its agencies. So one is exactly what you are describing, which is communication with the provider community to make sure that prescribing is appropriate, that utilization is appropriate. We are also looking at other facets, so medication-assisted therapy for substance abuse issues and the use of naloxone, for example, for emergent overdose issues.

CMS has a role to play in the broader kind of social landscape, and I think again, your point that this is not just a Part D issue but a kind of broader societal issue is exactly right. We are approaching it as a payer using every lever that we can from looking at prescribers to the beneficiaries that might be abusing the program, identifying pharmacies that might be part of the problem and working very closely with plan sponsors. One even sort of broader partnership that I would point out is the Health Care Fraud Prevention Partnership where we are working with not just Part D or C plan sponsors but the private sector generally, a number of private payers, to look at these issues and others. So we have done, for example, an outlier pharmacy study with this public-private partnership, identified 8,000 pharmacies not just in the Part D world but also in the private just of pure private payer world that we are now looking at and working kind of individually. So I completely agree that partnership is at the center of this. We are trying various approaches to partnership to help ameliorate the issue.

Mr. BUCSHON. Well, I mean, what does Anthem do, for example? I don't want to throw out any names, but big insurance companies that pay for that are a payer, right? Because for the narcotics, if there is a funding stream, people are going to look to the funding stream to try to obtain these medications. I mean, that is just human nature.

Is there anything the private sector companies are doing differently than maybe CMS is doing on that front?

Dr. AGRAWAL. Yes, also an important question. So I think one of the advantages of the construct of the Part D program is that we do work through the private sector. So the common payers that you could identify are Part D plan sponsors, and so we are able to utilize the exact same tools and approaches that they have in their pure private side for the advantage of Medicare, whether it is—

Mr. BUCSHON. So basically you are working through them. I know Medicare Part D works through plan sponsors. We have

talked about that. So you are basically working through them and using their techniques to try to tackle this problem?

Dr. AGRAWAL. Correct, correct, in addition to the other things that we can do from an agency kind of Federal leadership standpoint.

Mr. BUCSHON. OK. Thank you. I yield back.

Mr. MURPHY. Mr. Green, you are recognized for 5 minutes.

Mr. GREEN. Thank you, and I want to thank both of you for being here today, and I want to take a few minutes to talk about the recent successes in combating fraud and abuse in the Medicare program.

In June, HHS and the Department of Justice announced a sweep led by the Medicare Fraud Strike Force resulting in charges of 243 individuals for approximately \$712 million in false billing. This was the largest takedown in the Strike Force history. More than 44 of the defendants arrested were charged with fraud related to the Medicare Part D program.

Ms. Maxwell, the Office of Inspector General was an integral part of this takedown. Can you tell me more about the OIG's role?

Ms. MAXWELL. Absolutely. I would be happy to provide you more details about the national takedown.

As I mentioned, it is the largest criminal fraud takedown in the Medicare Strike Force history. About a third of the cases focused on Medicare Part D prescription drug fraud and also focused on Medicaid personal care services and Medicare home health. In particular, focused on the prescription drug, there were 44 defendants charged in related prescription drug fraud. We have—

Mr. GREEN. Go ahead. I was wondering, have those gone to trial yet or is it too early?

Ms. MAXWELL. Too early. So the takedown just happened last month, so we are still in the process of working through those.

Mr. GREEN. I understand the takedown involves a significant component of prescription drug fraud. Can you elaborate? Is this type of criminal fraud scheme increasing in prevalence in the Part D program?

Ms. MAXWELL. Yes. We have seen an increase of 134 percent of our Part D cases. We have 540 pending cases in Part D alone.

Mr. GREEN. OK. The Health Care Fraud and Abuse Control program, which funds the Medicare Fraud Strike Force, has recently seen record-breaking fraud and recovery efforts as well. In the fiscal year 2014 alone, the program recovered \$3.3 billion from individuals and companies facing healthcare fraud allegations. Since its inception in 1996, the program has recovered \$27.8 billion. The Affordable Care Act significantly increased funding for HCFAC, indexing the program's mandatory baseline and funding to inflation, providing over \$3 million in additional funding.

Ms. Maxwell, how can we build on these successes in the future?

Ms. MAXWELL. The HCFAC funding has been integral to the success of the OIG. It, as you mentioned, funds our Medicare and Medicaid operations both in investigations, audits and evaluations, and as we are looking at this Part D problem, that is the OIG's approach. We have recognized this as a priority and we are taking an all-hands-on-deck approach. So we are using those funds to use all the tools available to the OIG to focus on this issue.

Mr. GREEN. The ACA provided new authorities to combat waste, fraud, and abuse such as enhanced penalties for fraudulent providers. Ms. Maxwell, how are these new ACA authorities assisting the Inspector General in successfully combating Medicare fraud?

Ms. MAXWELL. The authorities have been incredibly helpful. We have been able to use our civil monetary penalty and exclusion authorities to help buttress and protect Medicare Part D.

Mr. GREEN. OK. Dr. Agrawal, same question.

Dr. AGRAWAL. Yes, the authorities in the ACA for CMS have also been very significant. You know, what it did 5 years ago was, it embarked us on a pathway of enrolling every single provider and supplier that is in the program, subjecting them to common and consistent screening standards, which have led to over 500,000 enrollments now being deactivated or revoked. Bottom line is, they can no longer bill the program. So that kind of screening approach has been, I think, extremely effective. We have also obviously implemented other approaches along the way like the predictive analytic system that we described earlier to really augment these enrollment activities.

Mr. GREEN. Thank you, Mr. Chairman. I yield back.

Mr. MURPHY. Thank you.

Mrs. Brooks is recognized next for 5 minutes.

Mrs. BROOKS. Thank you, Mr. Chairman.

I am a former United States attorney, and so used to be involved when I was in Medicare fraud-type of cases, and so I do want to commend you for this huge, massive sweep that just happened.

I am curious if you could share a little bit more about—during the time I was U.S. attorney, mortgage fraud was kind of overtaking the country and we had massive schemes involving mortgage fraud. Now it seems that we have massive schemes involving Medicare fraud, and I am curious whether or not in these investigations you have found are there connections between the different communities, and are there schemes that are more commonly being utilized than others, particularly with prescription drug issues? And I would like both of you to comment as to, you know, how prevalent were the identity theft issues in these prescription drug cases as well, whether it was identity theft of the beneficiaries or identity theft actually of prescribers? And I am just curious whether or not you were seeing any sort of certain types of enterprises and certain types of patterns bubbling up in these cases?

Ms. MAXWELL. Absolutely. We are seeing a wide range of fraud schemes emerging in Part D, certainly in the national takedown that just happened last month, and it can range from small physician or pharmacy to a full-on criminal enterprise.

One of the new schemes we have been seeing in the emergence of patient recruiters that go out and they are in the community, trusted individuals in the community that bring patients in to these schemes and bring them in as complicit beneficiaries. The fraud schemes in the takedown, we focused primarily on pharmacy fraud, and we see—for one example we saw in Miami, five pharmacy owners were charged with paying for beneficiaries' numbers so they could illegally bill and also paying a clinic provider to pro-

vide them adulterated prescriptions to bill for drugs they did not dispense.

Mrs. BROOKS. And so in these different schemes, particularly going back to the patient recruiters, were they also charged and were they conspiracy charges that were brought against these individuals? Do we have appropriate laws on the books to deal with all of the different actors in the schemes?

Ms. MAXWELL. I know that we are going after the entirety of the scheme and all the people involved. I am not a lawyer, so I would want to get back to you with specifics about our authorities to combat this.

Mrs. BROOKS. OK. I would be very interested in knowing whether or not if as the schemes—and we found this in the mortgage fraud issues of the 2000s, that people would be recruiting potential home buyers as well who really weren't going to be buying homes. And so I think we could see these kinds of schemes obviously happening here.

I am curious what DEA's role is, Dr. Agrawal. It is my understanding that you don't have authority to revoke licenses, that it has to go from DEA to a medical licensing board or to a pharmacy board. What is the type of work that you are doing with DEA and are there any impediments that you and/or DEA have with respect to revocation of licensing, which is a huge penalty for any pharmacist or any physician or prescriber?

Dr. AGRAWAL. Yes, I would agree with you that licensure either medical licensure or the specific, you know, schedule II authority that the DEA license gives you is incredibly important and valuable to, you know, legitimate prescribers. Those authorities, as you pointed out, are levied somewhere else, either at the State level and the State medical board or through DEA directly. But where we have really tried to get involved is making sure that our licensure information is up to date and that we are taking the relevant downstream actions from any licensure changes, whether it is a suspension or revocation or whatever.

The rulemaking that we engaged in last year that I mentioned earlier actually specifically links our revocation authority to the DEA license, and needing to have a valid DEA license in place actually prescribed in the program. So that is a place—you know, I think these are examples of where we can key off the work of other agencies as they engage in their oversight and enforcement responsibilities.

Mrs. BROOKS. Do you report anything to the licensing agencies of the States yourself?

Dr. AGRAWAL. We do. So we are able to make referrals informally to them about concerning prescribing habits, and we have done that. I think we see a wide degree of discrepancy between licensing boards that actually do something as a result versus not.

Mrs. BROOKS. OK. Thank you. I have nothing further. I yield back.

Mr. MURPHY. Mr. Tonko, you are recognized for 5 minutes.

Mr. TONKO. Thank you, Mr. Chair.

This subcommittee held a number of hearings earlier this year to examine the current opioids abuse epidemic. Dr. Agrawal, you mentioned in your testimony that the epidemic has touched all

parts of the Part D program. The spending for opioids has increased substantially over the past decade, and the number of prescription drugs overdose deaths is staggering, to say the least. We need to use all of the tools at our disposal to combat this problem.

Over the past several years, CMS has taken a number of steps to strengthen Medicare program integrity including measures to prevent overutilization of prescribed medications. In January 2013, CMS implemented the Medicare Part D Overutilization Monitoring System that requires plan sponsors to have a drug utilization management program in place.

So Dr. Agrawal, how does that system work so as to reduce potential opioid overutilization in the Part D program, and would statutory authority from plan sponsors to put so-called pharmacy lock-in programs in place complement that system?

Dr. AGRAWAL. Sure. The way the system works is, the agency identifies for plan sponsors those beneficiaries that have very high utilization of things like opioids using commonly accepted standards of, you know, sort of safety threshold. We provide those specific beneficiaries to the plan sponsors on a quarterly basis and then require them to take downstream utilization control steps including case management. What we have seen from the time that we have been doing this and working with plan sponsors in this way is a 30 percent reduction in the prevalence of those beneficiaries. So clearly, you know, impact is possible and we are looking to—and we continue to do this to ensure that we get as much impact as we can.

I think to the second question, you know, lock-in has been discussed, I think, quite a bit. We, you know, do view it as favorable and it does have, you know, good impact in the private sector as well as in various State Medicaid programs. It is part of the President's budget, and we look forward to working with this committee on getting that passed.

Mr. TONKO. And what is the role of the plan sponsors in identifying potential opioid overutilization?

Dr. AGRAWAL. Yes, the plan sponsors have a critical role, you know, throughout Part D whether it is with opioids or other schedule II drugs, other medications generally. You know, I think that is why we have highlighted making sure that they have robust compliance programs in place, robust utilization programs in place so they can address a wide array of issues. We also engage in a lot of data sharing with them, both about abusive prescribers, abusive pharmacies, outlier beneficiaries. You know, this is a partnership really to ensure the integrity of the Part D program. The agency and Part D plan sponsors really have to work very closely together.

Mr. TONKO. And the system has been in place about 2 years. Is that correct?

Dr. AGRAWAL. The OMS system?

Mr. TONKO. Right

Dr. AGRAWAL. I think that is right, yes.

Mr. TONKO. OK. And the data that are returning are showing great promise, I understand. Have you seen a reduction in the number of overutilizers in Part D?

Dr. AGRAWAL. Yes, we have, so again, of the beneficiaries that we have identified exceeding or meeting a certain safety threshold and that we have shared with plan sponsors. We have seen a 30 percent reduction or roughly 30 percent reduction in the prevalence of those beneficiaries.

We have also exchanged information about acetaminophen because it often is kind of coingested with opioids and is liver-toxic in and of itself, and there we have seen a 91 percent reduction in the prevalence of those at-risk beneficiaries.

Mr. TONKO. And you noted in your testimony that there are a number of additional tools in the President's 2016 budget. Those tools would prevent the inappropriate use of opioids. Can you elaborate on those offerings that he is presenting to us?

Dr. AGRAWAL. Sure. I think the main one that I can highlight we have discussed to some degree is the lock-in approach that would essentially restrict certain beneficiaries to, you know, based on kind of abusive utilization to select pharmacies and select prescribers, and that is an approach that has been utilized in the industry before. It is a way of trying to balance access to appropriate care and medications against that potentially abusive behavior. So that is something that we view as potentially having significant positive impact, and we hope this committee and others help to work with us on that.

Mr. TONKO. Thank you.

And Ms. Maxwell, the OIG Data Brief noted that there has been substantial growth in spending in Part D drugs, especially for commonly abused opioids. How can the OIG's recommendations to combat fraud and abuse help combat this situation, this problem?

Ms. MAXWELL. Similar to the conversation that you have just been having, we do recommend that a lock-in program be instituted to help address this problem.

Mr. TONKO. Thank you very much, Mr. Chair. I yield back.

Mr. MURPHY. The gentleman yields back.

I now recognize the gentleman from Oklahoma, Mr. Mullin, for 5 minutes.

Mr. MULLIN. Thank you, Mr. Chairman, and I thank both of you all for being here.

Doctor, I was just going over some of our notes on this, and I was disturbed because we have talked before, and we have talked about the abuse of opioids—it is not going to come out. Anyways, we know what we are talking about.

Mr. MURPHY. Opioids.

Dr. AGRAWAL. With narcotics.

Mr. MULLIN. Thank you, narcotics. And not enough coffee today.

Anyways, as we were discussing, some statistics came up, and we noticed that Part D spends on average, the beneficiaries, around \$105 per individual. In Oklahoma, we see that at \$165 per individual enrolled in Part D. And 43 percent of those enrolled in that receive this drug that is commonly abused. Doesn't that seem a little high to you?

Dr. AGRAWAL. I think Part D is like any other sector of healthcare. We have seen the increasing use of opioid medications throughout healthcare, whether that is in the public sector or in the private, you know, and again, I think we have to be careful.

I sort of take this as a physician to heart. There are people who have legitimate pain issues that need to be addressed with these powerful medications.

Mr. MULLIN. But 43 percent enrolled in it in the State of Oklahoma alone? I mean, that seems awfully high to me.

Dr. AGRAWAL. Yes, I agree, you know, that number does seem high. You know, I think the question that is very difficult for anyone to answer is what portion of that is the totally legitimate utilization that you would expect to see.

Mr. MULLIN. Well, in our previous hearing about Medicaid fraud and the addiction of these drugs, I asked you about the number of beneficiaries being prescribed methadone as a first line of defense, right? And then these numbers come out from last year, and by CMS' own recommendation, it says it shouldn't be used as a front-line defense. But yet, like I said, in Oklahoma, 43 percent of those enrolled in Part D beneficiaries are still receiving it. Abuse seems like it speaks for itself through numbers. As a business owner, I look at financial sheets all the time, especially when we would go in, we would go to purchase a company, I could look at the financial sheets and I could immediately tell you where the balances were messed up at, and what we would do when we would see something like that is, we would cut that part out to make the company profitable again. If we are seeing numbers like this, isn't it easy to say that until we get a hold of it, we should just cut it out? There are other drugs on the market. We don't have to be prescribing this stuff at the rate that we are. Until we understand it more or can oversee it in a better capacity, we should pull it. We do that all the time with drugs, don't we?

Dr. AGRAWAL. So, you know, I am not an addiction expert, and you know, I think—

Mr. MULLIN. You don't have to be.

Dr. AGRAWAL [continuing]. There clearly is a role—

Mr. MULLIN. The numbers speak for themselves. I don't know how many hearings we have had of this. We have even brought in a detective from Oklahoma that talked about it.

Dr. AGRAWAL. I think there is clearly a role for medication-assisted therapy in the substance abuse space. What we focus on rather than just eliminating a benefit for an entire group of people, some of whom might really actually need that benefit, is to try to cut away the waste, abuse, and fraud that may be occurring. So that is the role of things like the Overutilization Monitoring System that look at bennies—

Mr. MULLIN. I get that, but just last year we still had 43 percent in Oklahoma prescribed to it. I can't get that out of my head. You can't convince me that nearly half of those on the Part D need these type of prescribed drugs when it is not supposed to be the first line of defense. It sounds like to me it is an easy way for them to just prescribe it and move on.

There is not enough research being done to make sure that it is not being abused. We are putting people on this and they are blindly taking it because their physician prescribes it to them and then they are becoming addicted to it. Is this not throwing up red flags? Is there not something that we can do at a more aggressive rate than just simply looking into it?

Dr. AGRAWAL. Well, Congressman, I think you are pointing out what I think the agency has been saying is that this is a multifaceted issue. So whether you are talking about the patient or—

Mr. MULLIN. I know, but saying—

Dr. AGRAWAL [continuing]. Prescriber—

Mr. MULLIN [continuing]. Is two different things.

Dr. AGRAWAL. Correct, and that is why we are focused on doing with all of these different programs that we have that look at prescribers, that look at beneficiaries getting the drugs. We have programs around data transparency to send information to prescribers about their own prescribing habits so they can see how it compares to others.

I think this is a complex problem. I am not sure that a single number is something that the agency can respond to because it really, you know, matters what is underneath that number, what is the appropriate utilization that you would like to see.

Mr. MULLIN. And sir, I get that and I am out of time.

Thank you, Chairman, for indulging me there.

Mr. MURPHY. The gentleman yields back.

I recognize Ms. Castor for 5 minutes.

Ms. CASTOR. Well, thank you, Mr. Chairman, for calling this hearing. I think it is an important time for us to take a hard look at Medicare Part D. We are about 10 years into the existence of the program. We have 42 million Americans who rely on the benefit. A lot of the consternation was how it was constructed where you would get coverage and then you would reach a certain level of coverage and then fall off a cliff into a doughnut hole, and that made it very difficult for many of our neighbors to get the care that they need.

But thankfully, the Affordable Care Act has brought some significant reforms to Part D. Most important is closing the doughnut hole. As a result of the ACA, 9.4 million seniors and people with disabilities have saved over \$15 billion on their prescription drugs, an average of about \$1,600 per beneficiary.

And I wanted to pull up the statistics for the State of Florida and make sure they are on the record. Since 2010, overall savings for Florida's seniors under the Affordable Care Act now has been almost a billion dollars, \$979 million, and in 2014, Florida's seniors saw savings of about \$306 million. On average, that is about \$884 back into the pockets of our older neighbors, so that has been very beneficial.

And just as important as the savings to our neighbors is the overall savings to the program. OMB has deemed Medicare Part D a high error program, meaning it has an improper payment rate above a certain threshold, 3.3 percent, which amounts to \$1.9 billion in improper payments, and we have got to save these dollars. So I really appreciate the work that the IG and CMS has been doing.

Clearly, we have to do more, and I want to compliment the Medicare Strike Force, especially for the June takedown. In Florida, they arrested about 73 people. South Florida has been a problem area, and I am going to get into that a little bit more.

Ms. Maxwell, what is the explanation for the—I know you have said it multifaceted but break it down a little bit more. What is the explanation for the increasing cases of fraud nationwide?

Ms. MAXWELL. I think as we have been talking, there is a lot of money at stake that is enticing, and we are continuing to build the tools to protect the program. Our role in that is multifaceted. As you had mentioned, we have investigations where we actually go out to try and catch criminals who are defrauding the program, but we also have a role to audit and evaluate and make sure that there are systemic fixes. As I had mentioned in my oral, enforcement is never going to be enough. We need to look at the program as a whole and make sure that the plan sponsors have compliance programs in place to protect the program and that CMS also has strong resources to back that.

Ms. CASTOR. So your OIG report emphasizes two areas of opportunity to improve Part D program integrity, first, in the use of data to identify vulnerabilities, and second, an increased oversight by all parties responsible for protecting Part D, and I know this has to include the new emerging criminal networks, because what we saw in Florida, especially Miami, of people that have been convicted of drug trafficking had served their time, came out of prison and are now looking at Medicare Part D fraud. What can—what else do we need to be doing to combat these criminal networks, and explain to us what some of their schemes are under Part D?

Ms. MAXWELL. Absolutely. I think one of the things that we are doing very successfully now and have continued to focus on are the Medicare strike forces in which we partner with CMS and other local and State law enforcement to stay on top of this fraud and address these emerging issues as they hit the ground.

As you know, fraud is ever evolving, and so—

Ms. CASTOR. So one of the—I wish Mrs. Brooks was still here. She is a former U.S. attorney. One of the weaknesses has been the penalties, the criminal penalties. Do you agree?

Ms. MAXWELL. We could always—yes, we could strengthen our penalties.

Ms. CASTOR. OK. And Dr. Agrawal, does CMS need specific direction to require all plan sponsors to report all fraud information rather than keeping it strictly voluntary?

Dr. AGRAWAL. Sure. So as I mentioned earlier, we are working to evolve the reporting that is both given to plan sponsors as well as what they give back to us. We have started by focusing on leads, investigative leads, for plan sponsors to develop and then take any necessary administrative actions on. We implemented an IT system called PLATO earlier this year for them to be able to—

Ms. CASTOR. My time has run out. Could you just say yes, that would be helpful if it was mandatory rather than voluntary?

Dr. AGRAWAL. I think it could be helpful to help—you know, to continue to evolve the program and evolve the relationship between the agency and plan sponsors.

Ms. CASTOR. Thank you.

Mr. MURPHY. The gentlelady yields back.
Now Mr. Collins of New York.

Mr. COLLINS. Thank you, Mr. Chairman, and I want to thank my fellow committee members for the line of questioning we have had today.

So we had an interesting discussion, Dr. Agrawal, last time, if you remember, on Six Sigma Lean Six Sigma.

Dr. AGRAWAL. Yes, I don't totally remember it as a discussion but we had that conversation, I guess.

Mr. COLLINS. So let me pick up. After that meeting, what did you think, do or say when you went back to your office? What did you think, do or say when you went home that night? And did you take anything positive out of that discussion or whatever you want to call it?

Dr. AGRAWAL. I think where there are ideas that benefit the program that we can implement differently to improve the integrity of Medicaid, of Part D and Medicare, whatever the case may be, we take that input seriously, whether it comes from the committee, the OIG, the GAO, or others. So again, we take good ideas seriously and we work to implement them. It may not be instantaneous or overnight but the work is constant.

Mr. COLLINS. So afterwards, did you give any more thought to your 6.7 percent 5-star error rate that, if you were the FAA, you would allow 10 airplanes a week to crash and give yourself 5 gold stars, or did you understand the tone of any of that and did you take any of that back to say, "Oh, my God, a 6.7 fraud rate is not only not acceptable, it is certainly not a bell ringer to say you did a good job"?

Dr. AGRAWAL. Yes. You know, again, as I think we had communicated in that last discussion, you know, we are not tone deaf and we understand that there is work to be done. I look at that error rate and, you know, recognize that it needs to come down. You know, nothing about that line of questioning sort of augmented or changed the recognition.

Mr. COLLINS. Did you change your 6.7 to something lower or is your error rate this year still 6.7?

Dr. AGRAWAL. Sir, that is measured on an annual basis. It is not going to change day to day.

Mr. COLLINS. See, being a private-sector guy, well, if I was your boss, how long do you think you would work for me?

Dr. AGRAWAL. Sir, I have certain misgivings about thinking about working for you.

Mr. COLLINS. As you should. As you should.

Dr. AGRAWAL. Let me be clear about something perhaps. So I came to this job just over—

Mr. COLLINS. That was funny, by the way.

Dr. AGRAWAL. Thank you. I appreciate it.

Look, I appreciate the message that you are trying to send, and I appreciate the tone of the sort of last line of questioning last time. I think what I should have said then in response and what I say to you now is, I came to this job from the private sector. I have been a clinician. I have taken care of thousands of Medicare and Medicaid beneficiaries. My purpose is coming here was to help ameliorate, make progress on exactly these kinds of issues. I think what would be helpful is a collaborative approach. If we can do that, if we can work together on devising solutions and getting

them implemented, nothing would make me happier. I think merely pointing out that there is an error rate and kind of harping on it over and over doesn't help necessarily make that progress.

Mr. COLLINS. So, I mean, if you looked into Six Sigma Lean Six Sigma, as the county executive of the largest update county in New York that was effectively bankrupt when I took over, we took that county from number 62 to number one in 3 years. Three years after, I had 500 certified yellow belts, green belts, black belts, master black belts. My deputy county executive was a master black belt. We had so much money in our county 3 years in, we were paying cash for capital projects. We paid down \$150 million of our county debt. We had \$100 million county surplus in 3 years. Lean Six Sigma works but it starts with somebody at the top, in my case, the CEO of a county, but also it could be the head of quality control, the head of manufacturing, who comes in and says I don't want to accept 67,000 errors per million opportunities; I want zero, and I am going to measure that every day and I am going to chart that every day, and you know what? I am going to send myself and I am going to send others to schools, to training to find out how to process map an error.

What Dr. Burgess pointed out, and I got one of these phone calls the other day too, I got one from American Express. There was a \$25 innocuous charge. They said this looks like it could be fraud, and it turns out it was. That was 15 minutes after somebody put through that transaction. That is an organization that gets it. That is an organization that says we won't accept any errors, let alone 67,000.

So I guess as my time runs out, I would simply challenge you to dig into Lean Six Sigma more. It does work. It can be implemented in Government, but it starts with the person in charge, someone like yourself saying I just categorically reject the level of fraud or other errors and I am going to be proactive in finding out how to do it better, and I would just perhaps challenge you to look into this a little further.

And with that, I yield back.

Mr. MURPHY. The gentleman yields back.

I now recognize Ms. Clarke for 5 minutes.

Ms. CLARKE. Thank you, Mr. Chairman, and I thank our Ranking Member. I thank our witnesses. This is a very complex issue. There is no doubt about that. But the stakes are very high with respect to what is happening to the American people and the illicit prescription drug proliferation that is taking place in many parts of our Nation.

Ms. Maxwell, I think we all agree on the importance of ensuring drugs are prescribed and dispensed appropriately and legitimately. The Office of Inspector General's report suggests several ways to strengthen Part D program integrity efforts. The report recommends that CMS determine the effectiveness of programs and take action to ensure that sponsors' compliance plans meet CMS requirements.

So Ms. Maxwell, what more could be done to ensure that sponsors' fraud detection efforts are effective?

Ms. MAXWELL. Our recommendations point to mandating the reporting of fraud and abuse that sponsors identify as well as man-

dating the reporting of what sponsors do with that. We believe that comprehensive reporting from all plans would allow CMS the visibility and the tools to be able to assess the effectiveness of what is happening at the sponsor level.

Ms. CLARKE. So that sounds like a logistical challenge, right? You have several sponsors. Right now they voluntarily make that information available. Can you drill down a little bit deeper in terms of systems that could be established that either trigger some sort of an action on the part of CMS or what would you suggest? Because if it is voluntary, you know, they are operating businesses, they are sponsors. How do you sort of hold them accountable in the course of the time that they are spending doing all the other activities that they need to do to run their companies?

Ms. MAXWELL. Sure, and because they are required right now to report voluntarily, I would assume—and I would defer to Dr. Agrawal for the specifics—I would assume that there are processes for that reporting to happen. So the systems are in place. The question is, why isn't everyone using them. So when we look for the voluntary reporting, we only see 35 percent. So the other plans have the capacity; they have just opted not to do the reporting.

Ms. CLARKE. So Dr. Agrawal, is it an issue of at this stage voluntary just does not work and that it has to be a mandate?

Dr. AGRAWAL. Well, to answer your question, we have been working to enhance systems that allow plans to report data back to us. We implemented a major enhancement earlier this year that allows that data to not only be reported but also be kind of searchable so it can be utilized. What we have been doing is focusing on getting these plan sponsors better data about leads that they should be investigating and potentially taking action on. I think as we further that relationship, as we give them more data, we will be very interested in hearing back from them and perhaps in a mandate exactly what work that they have done. But we find that just by improving the system and improving the collaboration, we get better reporting.

Ms. CLARKE. So baked into what you are saying is that there was an assumption that there were some misgivings or misunderstanding of what exactly the sponsors were to do to report voluntarily? Is that sort of where the thinking is?

Dr. AGRAWAL. Well, I think that sponsors like many private companies have concerns about reporting data back, especially when it would be visible to other—you know, potentially visible to other plan sponsors. So one way that we have worked with them not just on the system enhancement side and making the process easier is, we actually allow them to report certain information deidentified of source. So they tell us a problematic pharmacy or problematic prescriber what they have done to take action against that entity or individual. But we are not—it is not necessarily clear to us which sponsor—or it can be sort of deidentified which sponsor put that in.

From a private-sector kind of competitive standpoint, that input made sense to us, and so we have taken as a step allowing them to input that kind of data so that we get better reporting about the actual problem, which is the fraud and abuse in the program.

Ms. CLARKE. So that can be a double-edged sword, right? They don't want the information attributed to them on the basis of some sort of a proprietary disadvantage. Is that what you are saying?

Dr. AGRAWAL. Well, I think, you know, there is a narrative that, you know, fraud and abuse just doesn't occur in the private sector. We have heard numerous committees kind of, you know, suggest that that is the case. I think, you know, you have programs like Part D which is conducted through the private sector and yet we see these problems. So, you know, I think what we have to do is get to a place where we are really doing the best we can to get all the right information from plans. As we develop that expertise, we can, you know, implement more stringent guidance, perhaps getting to the kind of mandate that OIG is requesting of us. But, you know, we are taking steps along that kind of evolutionary pathway.

Ms. CLARKE. Let me ask, Dr. Agrawal, there are some troubling findings that the GAO reported in 2014. CMS conducted audits of Part D plan sponsors in 2013. Of the plans the agency audited, there were fraud, waste, and abuse findings in nearly all of the audits, 94 percent. Specifically, CMS found inadequacies in plan sponsors' compliance training, resolution of fraud, waste, and abuse inquiries in a timely manner, and corrective actions taken in response to potential fraud, waste, and abuse. These are troubling findings, and I think it goes to my previous question. How does CMS evaluate the effectiveness of sponsors' compliance programs? Have these efforts changed recently? And what is CMS doing to follow up with the audited plans to ensure that these deficiencies are being remedied?

Dr. AGRAWAL. Thank you for the question. So we do conduct audits of—compliance audits of plan sponsors to make sure that they are compliant with our regulations, not only on the fraud, waste, and abuse side but also, you know, obviously inclusive of their program integrity work.

Recently, we have stepped up the amount of both the volume of audits that we do as well as the focus in making sure that program integrity is part of those audits. Where a deficiency is identified, we work with them like we would any other contractor, which is we can send letters of concern, we can place them on corrective action plans. There is an array of tools to get contractors into compliance with our expectations.

Ms. CLARKE. Thank you. I didn't realize I was so far over time. If you could send us something in writing—

Dr. AGRAWAL. Sure.

Ms. CLARKE [continuing]. That outlines that, that would be helpful.

Thank you. I yield back.

Mr. MURPHY. Thank you.

Mr. McKinley is recognized for 5 minutes.

Mr. MCKINLEY. Thank you, Mr. Chairman. Again, I apologize. I had to step out. We have a pipeline safety issue downstairs in another committee, and we just had a fire in a pipeline last week, and I needed to be there for that.

But back on this panel, a few months ago we had a discussion here about one of the big problems here with opioids was over-prescription, and I don't know that we came up with a solution how

we are going to address that because I don't think we want Congress to be practicing medicine. But then we got into a discussion, I think it was with, Doc, and that was over getting the prescription database in real time across the country to be able to have that so that we might be able to track the abuse that is happening that way. Are we making any progress on that from either one of you? Can you address that issue?

Ms. MAXWELL. The Inspector General has not done any work—you are talking about the prescription drug monitoring databases in the States, I take it?

Mr. MCKINLEY. In States they have—it is not in real time, it is within a week they will file the information. But the problem of abuse is because it is in real time. Someone goes across the river into Ohio or West Virginia or Kentucky and they are abusing the system. We have been talking about that, my goodness, for at least 3 years. I am just curious what progress we are making on that. We heard from the attorneys general who were all suggesting that is one of the best ways we could make progress in abuse within our Part D. I haven't heard what progress we are making.

Dr. AGRAWAL. Yes, so the implementation of PDMP, prescription drug monitoring programs, like the systems that you are describing are, you know, as you know, State-level initiatives. HHS has been involved in—

Mr. MCKINLEY. They can only do it statewide. I am talking about interstate, and that is where the catch comes into it because so many of us are in border States that we can cross easily over to where population is generally on a border. So help me out a little bit about where we are going from the Federal. Is there a role for us to play? Because you mentioned earlier, Doc, you said we need a collaborative effort. I am looking to see what do you need from us to help out, to make this collaborative effort.

Dr. AGRAWAL. Yes, that is a good question. So I think I would have to take that back in terms of, you know, the kind of interoperability issue that you are identifying or getting more States on board because as I mentioned, that is being done at the HHS level. There is less of a direct kind of CMS role in that set of activities. I am happy to take that back.

I will you from just sort of my experience as a clinician, you know, one way that States, you know, try to remedy this issue, and you see this sort of in the DC/Maryland/Virginia area, is by encouraging providers to get access to numerous different databases. Now, it is not a perfect approach but I will tell you, I have utilized that approach in my own practice just to make sure that, you know, a patient or a beneficiary is not crossing State lines to kind of game the system and get these medications.

Mr. MCKINLEY. I have less than 2 minutes. Let me go back to another statement you made to the Congressman from New York.

You said we need to have more collaborative effort. What did you mean by that? Is there something we are not doing? Because our whole role here is to try to be supportive. So are we not being collaborative?

Dr. AGRAWAL. No, and, you know, I appreciate the question. The comment wasn't really about the committee as a whole or anything like that. I think it is, from my perspective, a certain tone of ques-

tioning that I find to be less constructive, but it was not about the committee in general. In fact, I think there have been ideas exchanged in recent hearings and certainly even today that I think do demonstrate that kind of collaboration.

Mr. MCKINLEY. In the last minute that I have, I remember the issue was over the 6.7 percent, but where do we think—I am just curious, where should it be? If not 6.7, should it be 3, 2? Where do you—and is that the goal? Are we making progress or is it—have we plateaued at 6.7 or has it risen to 6.7? I don't know the trends. I am just curious. What can you share with us about the level of abuse?

Dr. AGRAWAL. Sure. So, if you look year on year, there is variability in the number, and there are two things that I think really have greatest impact on the number. One is, what are the requirements that we are implementing that either might be new requirements or that we are working to enforce more closely. What we find from a program integrity standpoint is that when there are new requirements or enforcement steps up, inherently the error rate tends to rise because even legitimate providers are not able to keep up with those changes. So it takes a period of education to actually get everybody into compliance. It then allows the trend to come back down.

Mr. MCKINLEY. Is the trend rising or is the trend going down?

Dr. AGRAWAL. I don't have the figures in front of me. I mean, there is year-on-year change, but we can get that to you.

Mr. MCKINLEY. Let us say over the 15 years, has the trend, is it increasing or decreasing?

Dr. AGRAWAL. We can go back as far as the error rate has been measured but we will share that with you.

Mr. MCKINLEY. Thank you very much.

Dr. AGRAWAL. Absolutely.

Mr. MCKINLEY. I yield back my time.

Mr. MURPHY. I think we all as Members have spoken here. There is a few things I want to just wrap up—oh, I am sorry. Mr. Griffith is here.

Ms. DEGETTE. And Mr. Bilirakis came in.

Mr. MURPHY. Mr. Bilirakis is here too. Then we will go with Mr. Griffith for 5 minutes. I am sorry.

Mr. GRIFFITH. That is all right. Thank you, Mr. Chairman.

Mr. MURPHY. You snuck in on me.

Mr. GRIFFITH. Mr. Chairman, first I would ask unanimous consent to insert into the record a statement from the National Community Pharmacists Association.

Mr. MURPHY. Without objection.

[The information appears at the conclusion of the hearing.]

Mr. GRIFFITH. Let me go to Mr. McKinley's question real quick, and I understand that, you know, maybe Maryland, DC, and Virginia, you can check that, but there are some real difficulties from my district. If you count the Commonwealth of Virginia, you can actually, if you work it out really well, you could hit five States in a single day. So I do think we need to be looking at some way that doctors can check because you get down there in that little corner of Virginia and you are touching West Virginia, Kentucky, Tennessee and North Carolina all within a matter of, you know, 45

minutes to an hour. So you could—you would have to work it. You would have to be at the doorstep of somebody first thing in the morning but you could hit five States in a single day. So I would ask you to take a look at what Mr. McKinley raised.

Now, my question also is about the methodology used in the OIG report on questionable billing practices. We all want to stop these things. We want to stop folks from abusing the opioids, et cetera. As the five factors you used seemed cut and dried without much room for additional consideration, my concern is that these results could present a broad generalization about pharmacies which may not paint the whole picture. For example, as I just described to you, I represent a fairly rural area, and that area has a higher percentage of senior citizens than the Nation as a whole. So a pharmacy might dispense a higher percentage of pain relievers when compared to other pharmacies in a different geographic or demographic area simply because there are not as many pharmacies around and perhaps the other pharmacies have a younger population that they serve.

It also would not be unreasonable to expect them to have a higher dispensation of controlled substances from a pharmacy located near a hospital or a surgery center or an oncology center. There are also pharmacies who are contracted providers for long-term care facilities and hospices. So how does CMS plan to address the results from the study that truly target the bad actors that we all want to get to without hitting the good guys who are just trying to serve their customers? And this came up earlier as a part of a complaint because one of my rural pharmacies has one supplier for their medicines, and at one point they got cut off and so they were having to tell their customers yes, I can't fill it today, come back at the end of the week when we change months. Well, that is hard if you are a senior citizen and you need that pain medication, and in fact, a friend of mine's wife was told that who had just gone through some surgery. She had to wait 3 days. They managed, but that is really not the way it ought to work, whether you would be in the urban areas in the northern part of Virginia, Maryland, and DC or you are in southwest Virginia in the rural areas. How do we fix it?

Dr. AGRAWAL. Yes, I think you make a good point. You know, this kind of data analysis is a starting point and, you know, I think as to the specific methodology, I will defer a bit to the OIG. But you know, data analysis is always the beginning point of our investigations. Now, I had shared earlier that on a month—on a quarterly basis, we send lists of concerning or high-risk pharmacies to Part D plan sponsors. Our methodology takes 16 variables into account, and in order for a pharmacy to make it onto the list, they have to be a statistical outlier in at least four of the variables. So the purpose there is to do exactly what you are describing, which is try to bring a little more specificity to the methodology. But again, after that follows the investigation. I think it is really challenging unless the data is extremely cut and dry, which occurs in rare situations, to take administrative action without the ensuing investigation in between. That is where we really try to get to the bottom of, is something really bad happening here or is this just

an outlier, but it is explained by certain geographic factors that you have identified.

Mr. GRIFFITH. I appreciate it very much. I appreciate you all being here today. I apologize. I too have been—we have got pipeline issues as well, as you might imagine, and I was in the other hearing.

Mr. Chairman, I appreciate your time, and I yield back.

Mr. MURPHY. The gentleman yields back.

I now recognize Mr. Bilirakis from the full committee for 5 minutes.

Mr. BILIRAKIS. Thank you, Mr. Chairman. I appreciate it. Thanks for holding the hearing. Thanks for allowing me to participate today.

Medicare Part D has been an important addition to the Medicare program, one of the most successful programs, I think, in the history of the Congress. It is a program that my constituents love and something that Congress should be proud of.

However, I have been concerned about the growing prescription drug problem in the United States and within the Medicare program. That is why in 2013 myself and our colleague, Ben Ray Lujan, first introduced the Medicare Part D Patient Safety and Drug Abuse Prevention Act, which would create a drug management program to prevent physician shopping and pharmacy shopping within the Medicare program. I am proud that we were able to include it in the 21st Century Cures bill that we passed last week.

It is important to the Medicare program to bring a commonsense provision that has been used in Medicaid, Tricare and commercial insurance. It also makes reforms to the MEDIC program in keeping with some of the OIG recommendations. That is the 21st Century Cures bill that makes those reforms.

The first question is for Ms. Maxwell. In your testimony, you talk about the need for a lock-in program in Medicare Part D to deal with prescription drug abuse and the problem of drug diversion. Do you have any estimate on the size of the problem? How many people and how much money are being lost to prescription drug abuse?

Ms. MAXWELL. I don't have those specific figures but I do have the figures in our Data Brief that the growth in prescribing opioids has been significant. It has been a 156 percent increase since the beginning of the program, which outpaces the growth in the general program. And so it is a continuing concern. We also have seen a tremendous increase in complaints against Part D so we have significant concerns about this. We do as a result recommend the lock-in. As you mentioned and as I think we have been talking about different ways to deal with doctor shopping, which can result either in patient harm or the diversion of opioids into the street. One way would be the PDMP to provide access to data around this issue and across State lines by the way is this lock-in, I mean specifically directed at that issue.

Mr. BILIRAKIS. Very good. Thank you.

Dr. Agrawal, I am sorry if I mispronounced. I just got here. In 2014, CMS issued rules for Part D and stated that they had the authority to remove abusive prescribers from the Medicare program. Can you give me an update on this? How many abusive pre-

scribers have been identified in the Medicare program and how many prescribers have been removed from the Medicare program?

Dr. AGRAWAL. Sure. So yes, you know, this is part of our overall approach to extending our enrollment requirements into Part D, so what we have been working on is getting prescribers enrolled. I think I mentioned earlier that there are 400,000 prescribers that have written prescriptions in Part D that we are working to enroll. We are also working to develop exactly the kind of cases that you are identifying, so through proactive data analysis, kind of starting to tee up these cases for the first time. I am not sure that we have conducted a specific revocation action using only that authority yet. Usually we try to do them in combination, and we may have added that authority to kind of another revocation action but I can look into whether there is a case that we uniquely utilized that authority.

Mr. BILIRAKIS. Thank you. One more question, Mr. Chairman.

Ms. Maxwell and Dr. Agrawal, when the MEDICs investigate a case and finish their investigation, I am assuming it is automatically referred to DOJ. Is that the case?

Ms. MAXWELL. I believe they do make referrals as part of their requirements.

Mr. BILIRAKIS. OK. If DOJ chooses not to pursue the case, maybe because of the view that the fraud is too small to be worth their time, does the information get automatically referred to State and local agencies or State licensing authorities? Can you answer that question?

Ms. MAXWELL. I am not aware of that specific mechanism. I do know that we are concerned when law enforcement action doesn't take place, that there are no mechanisms and processes to refer it for recovery of the inappropriate payments.

Mr. BILIRAKIS. How about, are Part D plan sponsors provided updates by the MEDICs? How does the MEDIC work with local authorities and State licensing agencies?

Ms. MAXWELL. Again, I am not familiar with the specifics. Perhaps Dr. Agrawal is—

Dr. AGRAWAL. Sure. So the MEDIC—I think this was in the testimony—MEDIC provided 2,300 referrals to law enforcement over the last, I think it is 5 years. Obviously we try to refer as much over to law enforcement as we can that we think kind of meets the threshold for law enforcement activity and investigation.

Where law enforcement doesn't accept a case, we have a few options. We have shared information with State medical boards to try to get action on their part. We regularly share information with Part D plan sponsors. We do that on a routine basis as well as an ad hoc basis if new issues come up or there are new entities or individuals that become concerning.

I think the threshold of our authority currently, you know, there is the, you know, OIG recommendation around recovery of dollars that Ms. Maxwell discussed. I think there are certain limits in our authority that prevent us from going directly to, say, a pharmacy and requesting recovery of those dollars. We do have to work through Part D plans, but there are a variety of avenues to do just that.

Mr. BILIRAKIS. Very good. Thank you. Thank you, Doctor. Thank you, Ms. Maxwell. I appreciate it, Mr. Chairman, and I yield back.

Mr. MURPHY. Thank you. The gentleman yields back.

I do want to follow up. The committee sent a letter to CMS seeking information about the improper-payment rate and that response is due tomorrow. Will the committee receive that response tomorrow?

Dr. AGRAWAL. We have been working diligently on it. I think you will get the response tomorrow.

Mr. MURPHY. Thank you. By the way, you seemed to suggest something earlier that the ACA is causing an improper-payment rate to rise. Is that—did we misunderstand that?

Dr. AGRAWAL. No. I don't know if this was perhaps your line of questioning. No. What I had said is that, you know, in the program integrity world, what we see often is that the improper-payment rate rises when there are new, stringent requirements that providers must meet, whether that is documentation requirements, enrollment requirements or other. So for example, the 6.7 rate that we discussed last time in Medicaid is largely driven by providers needing to enroll in Medicaid programs and States having adequate resources and systems to conduct that enrollment activity. I don't think anybody doubts the importance of enrollment. We talked about that as one of the major levers that we are now implementing in Part D that I think will be quite useful. We have already seen its impact in the rest of Medicare. But like any other requirement or standard, it can be hard for providers to keep up and that can sometimes result in the improper-payment rate going up.

Mr. MURPHY. All right. Well, we want you to continue to stay on that.

Ms. Maxwell, thank you so much. We do appreciate all that your offices do. It means a lot to this committee.

The next time we see you, Dr. Agrawal, I hope you will give me a report that all those have been put into place. As you know, some have been sitting around for nearly 10 years, and that is just not acceptable. So we thank you.

I thank all the witnesses and Members who participated in today's hearing. I remind Members they have 10 business days to submit questions for the record. We will have a number of those and ask the witnesses to respond promptly to the questions.

And with that, this committee is adjourned.

[Whereupon, at 12:15 p.m., the subcommittee was adjourned.]

[Material submitted for inclusion in the record follows:]

PREPARED STATEMENT OF HON. FRED UPTON

Medicare Part D is a critically important program for our Nation's seniors. Unfortunately, similar to our other entitlement programs, Medicare Part D remains vulnerable to fraud and abuse. Just last month, the Medicare Task Force conducted a nationwide Medicare fraud takedown. This joint law enforcement operation led to charges against 243 individuals for approximately \$712 million in false billings. While this was an important effort, much more needs to be done.

According to recent reports from the Department of Health and Human Services Office of Inspector General, the Centers for Medicare and Medicaid Services needs to take additional actions to strengthen the integrity of the Medicare Part D program. The reports find CMS is either failing or refusing to implement commonsense recommendations issued by its OIG. For example, CMS needs to ensure excluded

providers are not allowed to continue to bill under Part D. Additionally, CMS should require plan sponsors to report potential fraud and abuse. Implementing these recommendations is especially important in light of the startling increase in Medicare Part D spending on commonly abused opioids.

Medicare Part D is an expansive program, requiring constant vigilance. Just as bad actors will continue to try to find ways to take advantage of the program, we must take proactive steps to protect the program's integrity, taxpayers' dollars, and our Nation's seniors. A good first step is CMS implementing the OIG's recommendations.



U.S. HOUSE OF REPRESENTATIVES
COMMITTEE ON ENERGY AND COMMERCE

July 10, 2015

TO: Members, Subcommittee on Oversight and Investigations

FROM: Committee Majority Staff

RE: Hearing entitled “Medicare Part D: Measures Needed to Strengthen Program Integrity.”

On July 14, 2015, at 10:00 a.m. in 2322 Rayburn House Office Building, the Subcommittee on Oversight and Investigations will hold a hearing entitled “Medicare Part D: Measures Needed to Strengthen Program Integrity.”

Medicare Part D is the fastest-growing component of the Medicare program. Between 2006 and 2014, spending for Part D drugs increased by 136 percent, going from \$51.3 billion to \$121.1 billion. As a result of the program’s growth in spending, Part D has been vulnerable to fraud. On June 18, 2015, the Department of Justice announced that a nationwide sweep led by the Medicare Fraud Strike Force resulted in charges against 243 individuals for their participation in fraud schemes involving approximately \$712 million in false billings.¹

In conjunction with the nationwide takedown, the Department of Health and Human Services (HHS) Office of Inspector General (OIG) released two reports in June 2015, which highlighted potential fraud and abuse as well as identified systematic weaknesses that make Part D fraud and abuse possible. Given the substantial Federal dollars spent on Medicare Part D, and evidence of fraud and abuse in the program, the Subcommittee is conducting oversight to ensure that the program operates more effectively and tax dollars are spent efficiently. In particular, this hearing will examine the findings of two recent HHS OIG reports, “Ensuring the Integrity of Medicare Part D,” available here: <http://oig.hhs.gov/oei/reports/oei-03-15-00180.pdf>,² and “Questionable Billing and Geographic Hotspots Point to Potential Fraud and Abuse in Medicare Part D,” available here: <http://oig.hhs.gov/oei/reports/oei-02-15-00190.pdf>.³

¹ U.S. Dep’t. of Justice, *National Medicare Fraud Takedown Results in Charges Against 243 Individuals for Approximately \$712 Million in False Billing*, June 18, 2015, available at <http://www.justice.gov/opa/pr/national-medicare-fraud-takedown-results-charges-against-243-individuals-approximately-712>.

² U.S. Dep’t of Human Services, Office of Inspector Gen., *Ensuring the Integrity of Medicare Part D*, OEI-03-15-00180 (June 2015).

³ U.S. Dep’t of Human Services, Office of Inspector Gen., *Questionable Billing and Geographic Hotspots Point to Potential Fraud and Abuse in Medicare Part D*, OEI-02-15-00190 (June 2015).

Majority Memorandum for July 14, 2015, Subcommittee Oversight and Investigations Hearing
Page 2

I. WITNESSES

- Ann Maxwell, Assistant Inspector General, Evaluation and Inspections, Office of Inspector General, U.S. Department of Health and Human Services
- Shantanu Agrawal, M.D., Deputy Administrator and Director, Center for Program Integrity, Centers for Medicare and Medicaid Services, U.S. Department of Health and Human Services

II. BACKGROUND

Medicare Part D Facts and Figures

Medicare Part D was established by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 to provide an optional prescription drug benefit for Medicare beneficiaries.⁴ This program started on January 1, 2006, and there are approximately 39 million beneficiaries who receive Part D supplemental coverage for outpatient prescription drugs through more than 2,000 plans sponsored by private companies.⁵ Payments for Part D drugs in 2014 were approximately \$121 billion per year, which was up by 136 percent from 2006 when payments were \$51.3 billion per year.⁶ The Centers for Medicare and Medicaid Services (CMS) is responsible for the oversight of the Part D program.⁷

June 18, 2015 National Medicare Fraud Takedown

On June 18, 2015, the Department of Justice announced a nationwide Medicare fraud takedown, which led to charges against 243 individuals for approximately \$712 million in false billing.⁸ More than 44 of the defendants arrested were charged with fraud related to Medicare Part D, which, according to the Administration, is the fastest-growing component of the Medicare program. The defendants were charged with various health care fraud-related crimes, including conspiracy to commit health care fraud, violations of the anti-kickback statutes, money laundering, and aggravated identity theft.

Following the takedown, the OIG released two reports—a data brief and a portfolio—on Medicare Part D. The reports highlighted potential fraud and abuse as well as identified systematic weaknesses that make substantial Part D fraud and abuse possible.

⁴ U.S. Dep't of Human Services, Office of Inspector Gen., *Ensuring the Integrity of Medicare Part D*, OEI-03-15-00180 at 1 (June 2015).

⁵ *Id.*; Kaiser Family Foundation, *Medicare at a Glance*, Fact Sheet (August 2014), available at <https://kaiserfamilyfoundation.files.wordpress.com/2014/09/1066-17-medicare-at-a-glance.pdf>.

⁶ *Id.* The \$121 billion represents the negotiated payment to pharmacies, which includes not just federal government contributions, but also beneficiaries' co-payments and co-insurances.

⁷ *Id.*

⁸ U.S. Dep't. of Justice, *National Medicare Fraud Takedown Results in Charges Against 243 Individuals for Approximately \$712 Million in False Billing*, June 18, 2015, available at <http://www.justice.gov/opa/pr/national-medicare-fraud-takedown-results-charges-against-243-individuals-approximately-712>.

Majority Memorandum for July 14, 2015, Subcommittee Oversight and Investigations Hearing
Page 3

OIG Data Brief, Questionable Billing and Geographic Hotspots Point to Potential Fraud and Abuse in Medicare Part D

The HHS OIG data brief was based on an analysis of prescription drug event (PDE) records from 2006 to 2014. In its data brief, the OIG described trends in spending for Part D drugs and identified questionable billing associated with pharmacies, prescribers, and beneficiaries. From 2006 to 2014, Part D spending increased by 136 percent, from \$51.3 billion to \$121.1 billion. The total number of beneficiaries receiving commonly abused opioids grew by 92 percent, compared to 68 percent for all drugs. The average number of prescriptions for commonly abused opioids per beneficiary grew by 20percent, compared to three percent for all drugs. More than 1,400 pharmacies had questionable billing for Part D drugs in 2014. Together, these pharmacies billed \$2.3 billion to Part D in 2014 alone. Further, OIG identified pharmacy-related fraud schemes in Part D, including drug diversion, billing for drugs that are not dispensed, and kickbacks.

OIG Portfolio, Ensuring the Integrity of Medicare Part D

The HHS OIG portfolio was an overview of the OIG's investigations, audits, evaluations, and legal guidance related to Part D. In this portfolio, the OIG reported that Part D remains particularly vulnerable to fraud, resulting in an increase in Part D fraud complaints since the program's inception. As of May 2015, the OIG had 540 pending complaints and cases, a 134-percent increase in the last five years. Further, CMS does not currently require plan sponsors to report information on fraud, so less than half of sponsors choose to do so.

The OIG's portfolio highlighted several vulnerabilities and weaknesses exposing Medicare Part D to waste, fraud, and abuse. For example, excluded providers have been allowed to continue to prescribe Medicare Part D drugs. The Medicare Drug Integrity Contractor (MEDIC)—a private company which CMS contracts with to detect fraud, waste, and abuse in Part D—has conducted very little proactive data analysis to detect fraud waste, and abuse, which has allowed questionable billing and improper billing to go undetected. Part D inappropriately paid for drugs ordered by individuals who do not have the authority to prescribe, such as massage therapists and athletic trainers. Part D has also inappropriately paid for Schedule II drugs billed as refills. Because Schedule II drugs have a high potential for abuse and diversion, and are considered dangerous, Federal law prohibits refilling them. The OIG also found that Part D has continued to allow payments on behalf of deceased beneficiaries.

Further, the OIG has nine outstanding recommendations that CMS has not implemented that would greatly reduce the risk of fraud and abuse in the Part D program. All of these recommendations were issued to CMS in at least one previous OIG report, and in some instances, up to five previous reports dating back to 2006. The nine outstanding recommendations include:

- Require plan sponsors to report all potential fraud and abuse to CMS and/or the MEDIC (Recommended in October 2008, October 2009, February 2012, May 2012, and March 2014).

Majority Memorandum for July 14, 2015, Subcommittee Oversight and Investigations Hearing
Page 4

- Require plan sponsors to report data on the inquiries and corrective actions they take in response to incidents of fraud and abuse (Recommended in October 2008 and February 2012).
- Expand drug utilization review programs to include additional drugs susceptible to fraud, waste, and abuse (Recommended in August 2014).
- Implement an edit to reject prescriptions written by excluded providers (Recommended in December 2011).
- Exclude Schedule II refills when calculating final payments to plan sponsors at the end of each year (Recommended in September 2012).
- Restrict certain beneficiaries to a limited number of pharmacies or prescribers (Recommended in August 2014).
- Develop and implement a mechanism to recover payments from plan sponsors when law enforcement agencies do not accept cases (Recommended in January 2014).
- Determine the effectiveness of plan sponsors' fraud and abuse detection programs (Recommended in October 2008, February 2012, and March 2014).
- Ensure that plan sponsors' compliance plans address all regulatory requirements and CMS guidance (Recommended in December 2006).

III. ISSUES

The following issues may be examined at the hearing:

- Does CMS agree with the OIG's recommendations?
- Why has CMS not implemented the OIG's recommendations?
- What specific actions does CMS plan to take to address OIG's recommendations?
- Is CMS using all the tools at its disposal to mitigate vulnerabilities in the Medicare Part D program?

IV. STAFF CONTACTS

If you have any questions regarding this hearing, please contact Jessica Donlon, Alan Slobodin, or Brittany Havens of the Committee staff at (202) 225-2927.



WWW.NCPANET.ORG

July 14, 2015
Statement of the National Community Pharmacists Association
Hearing: "Medicare Part D: Measures Needed to Strengthen Program Integrity"
Subcommittee on Oversight and Investigations
Committee on Energy and Commerce

Chairman Murphy, Vice Chairman McKinley, Ranking Member DeGette, and members of the Committee,

Please accept the following comments providing the thoughts and recommendations of the National Community Pharmacists Association (NCPA) regarding the findings of two recent Office of Inspector General (OIG) reports on Medicare Part D program integrity that are the focal point of this hearing. NCPA represents the interests of pharmacist owners, managers and employees of nearly 23,000 independent community pharmacies across the United States. Together they employ over 300,000 full-time employees and dispense nearly half of the nation's retail prescription medicines.

Independent community pharmacists are proud to play a vital role in the Medicare Part D program, and have been on the front lines of providing medications, related counseling, and assistance with plans since the inception of the Part D program. More than any other segment of the pharmacy industry, independent pharmacies are often located in the underserved and rural areas that are home to many Medicare recipients. While NCPA remains supportive of efforts to prevent and reduce fraud, waste and abuse within the Medicare Part D program, they must be delicately balanced with ensuring appropriate patient access to vitally important medications.

NCPA is Strongly Supportive of OIG Recommendations to Require Part D plan sponsors to Report Potential Fraud and Corrective Actions Taken by Plans to CMS

The OIG states that although the Centers for Medicare and Medicaid Services (CMS) currently encourages Part D plan sponsors to report potential fraud and abuse or the steps taken by the plan sponsor to detect or stop it, this is not required. In addition, the OIG found that less than 50% of plan sponsors currently report this information to CMS. NCPA is supportive of this proposed requirement that would enable CMS to conduct more detailed data analyses of this type of activity in order to more accurately identify potential trends or troublesome patterns. The OIG mentions measures that have already been suggested to CMS including requiring plans to implement an edit to reject prescriptions when written by excluded providers. NCPA supports this proposal specifically and we are actively engaged with CMS and industry partners to implement this requirement.

Related to improved drug utilization controls for other drug classes, NCPA cautions CMS on expansion of controls into other drug classes at this time. Community pharmacy is a heavily regulated profession, and pharmacists are expertly trained to monitor and address cases of overutilization. Although we understand the need to more closely monitor the use of acetaminophen (APAP) and opioids in the Part D program, we are opposed to any expansion to other classes at this time. There are also efforts led by CMS to reduce the use of antipsychotic medications in long term care (LTC) settings, through initiatives such as the National Partnership to Improve Dementia Care. We are concerned that imposing additional controls at this time is unduly burdensome and could impact timely care for our patients.

The OIG also indicates that the Medicare Drug Integrity Contractors (MEDICs) do not currently use data analysis to detect potential fraud and abuse in a majority of investigations. In the past, some parties in the

THE VOICE OF THE COMMUNITY PHARMACIST

100 Daingerfield Road
 Alexandria, VA 22314-2888
 (703) 683-8200 PHONE
 (703) 683-3619 FAX

industry have been reluctant to support a measure to turn over such data to private contractors in the absence of a requirement that plan sponsors be similarly required to submit such data to CMS itself. NCPA is supportive of the expanded use of MEDICs provided that plan sponsors are also required to turn over the same data to CMS.

NCPA Categorically Opposes Any Attempt by Part D Providers to Circumvent Rules and Regulations but Recommends that Corrective Action be Targeted and Caution Used to Ensure Beneficiary Access to Legitimate and Needed Medications

NCPA opposes any attempts by Part D providers to circumvent rules and regulations and professional standards of practice but notes that the five measures used to identify “questionable pharmacy billing practices” in the OIG reports by themselves may not tell the entire story. For example, a pharmacy may dispense a high percentage of controlled substances when compared to other pharmacies in a particular geographic area; however, this could be due to factors such as the pharmacy in question serves a large number of oncology practices, is a contracted pharmacy provider for long-term care facilities, or is located next to a physician office specializing in pain management. In addition, another one of the “red flags” as noted by the OIG includes “the average number of prescriptions per beneficiary.” This factor, in and of itself, may not necessarily signal questionable billing on the part of the pharmacy but rather may indicate an overprescribing issue by one or more medical professionals.

NCPA cautions against simply using the five factors stated in the OIG reports to definitively identify a particular pharmacy as using “questionable billing.” As noted in the above examples, some of these factors could easily be attributed to other legitimate factors.

Any Proposal to Restrict Certain Beneficiaries to a Limited Number of Pharmacies or Prescribers Must be Carefully Tailored and Include Critical Beneficiary Protections

Another prior OIG proposal that is noted in the two reports under discussion today would allow plan sponsors to restrict certain beneficiaries to a limited number of pharmacies or providers. Historically, NCPA has had concerns with proposed “lock-in” proposals primarily due to the fact that without detailed beneficiary protections, some patients may experience delays in accessing much needed pain medications. Another secondary, yet considerably significant issue from a market fairness perspective is that a number of Medicare Part D plan sponsors have existing commercial relationships with certain large chains or with their proprietary mail-order pharmacy operations, raising serious conflict of interest concerns if the plan has the ability to “assign” a beneficiary to a particular pharmacy.

It should be noted that in virtually all of the 46 state Medicaid “lock-in” programs, the beneficiary retains the ability to choose both the in-network prescriber and pharmacy. There are currently several federal legislative proposals on this topic that would allow the beneficiary to “indicate preferences” for those providers and pharmacies that the beneficiary “would prefer the PDP sponsor select.” This language is not clear enough and ultimately vests the PDP sponsor with the authority to make the selection for the beneficiary which could create a serious conflict of interest issue – if plan sponsors can assign beneficiaries to a pharmacy in which they have a financial interest. NCPA strongly encourages that any legislative proposals on this topic be amended to change “preferences” to “choices.” Patients deserve to play an active role in how their health care is provided.

Conclusion

NCPA appreciates the opportunity to provide our comments and suggestions on the two recent OIG reports and stands committed to work with all government and industry stakeholders to combat fraud, waste and abuse in Medicare Part D.

FRED UPTON, MICHIGAN
CHAIRMAN

FRANK PALLONE, JR., NEW JERSEY
RANKING MEMBER

ONE HUNDRED FOURTEENTH CONGRESS
Congress of the United States
House of Representatives
COMMITTEE ON ENERGY AND COMMERCE
2125 RAYBURN HOUSE OFFICE BUILDING
WASHINGTON, DC 20515-6115
Majority (202) 225-2927
Minority (202) 225-3641

August 5, 2015

Dr. Shantanu Agrawal
Deputy Administrator and Director
Center for Program Integrity
Centers for Medicare and Medicaid Services
7500 Security Boulevard
Baltimore, MD 21244

Dear Dr. Agrawal:

Thank you for appearing before the Subcommittee on Subcommittee on Oversight and Investigations on Tuesday, July 14, 2015, to testify at the hearing entitled "Medicare Part D: Measures Needed to Strengthen Program Integrity."

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

Also attached are Member requests made during the hearing. The format of your responses to these requests should follow the same format as your responses to the additional questions for the record.

To facilitate the printing of the hearing record, please respond to these questions and requests with a transmittal letter by the close of business on Wednesday, August 19, 2015. Your responses should be mailed to Jessica Wilkerson, Oversight Associate, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, D.C. 20515 and e-mailed in Word format to jessica.wilkerson@mail.house.gov.

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,



Tim Murphy
Chairman
Subcommittee on Oversight and Investigations

cc: Dianna DeGette, Ranking Member, Subcommittee on Oversight and Investigations

Attachments

Dr. Agrawal's Hearing
"Medicare Part D: Measures Needed to Strengthen Program Integrity"
Before
E&C O&I Subcommittee

July 14, 2015

Attachment 1—Additional Questions for the Record

The Honorable Susan W. Brooks

1. **The total number of beneficiaries receiving commonly abused opioids (Schedule II and Schedule III drugs) grew by 92 percent, compared to 68 percent for all drugs. Similarly, the average number of prescriptions for commonly abused opioids per beneficiary grew by 20 percent, compared to 3 percent for all drugs.**
 - a. **What do you attribute this large increase to?**
 - b. **Why was there such a dramatic increase for commonly abused opioids compared to all other drugs?**

Answer to 1a & b: The Part D program has not been immune from the nationwide epidemic caused by the expanded availability of prescription opioid medicines and their non-medical use. We have seen the increasing use of opioid medications throughout the healthcare system, including both the public sector and the private sector. The causes for this dramatic increase are multi-faceted and will require a comprehensive approach, including educating beneficiaries/patients, prescribers, pharmacies, and plan sponsors. In March, Secretary Burwell announced a targeted initiative aimed at reducing prescription opioid and heroin related overdose, death and dependence.

The Secretary's efforts focus on three priority areas that tackle the opioid crisis, significantly impacting those struggling with substance use disorders and helping save lives:

1. Providing training and educational resources, including updated prescriber guidelines, to assist health professionals in making informed prescribing decisions and address the overprescribing of opioids.
2. Increasing use of naloxone, as well as continuing to support the development and distribution of the lifesaving drug, to help reduce the number of deaths associated with prescription opioid and heroin overdose.
3. Expanding the use of Medication Assisted Treatment (MAT), a comprehensive way to address the needs of individuals that combines the use of medication with counseling and behavioral therapies to treat substance use disorders.

Addressing the opioid crisis is a top priority for the department and the Secretary is committed to bipartisan solutions and evidence informed interventions to turn the tide against opioid drug related overdose and misuse.

c. Is CMS concerned by this trend? What is it doing to combat commonly abused opioids from stopping this trend?

Answer: CMS shares the deep concerns raised by this Committee and numerous other stakeholders about the increasing overutilization of opioids. Since 2013, CMS has been using the Medicare Part D Overutilization Monitoring System (OMS) to monitor Part D plan sponsors' drug utilization management programs to prevent overutilization of these medications. Using OMS, CMS provides quarterly reports to sponsors on beneficiaries with potential opioid or acetaminophen overutilization identified through analyses of prescription drug event (PDE) data. Sponsors are expected to use various drug utilization monitoring tools, including: (1) formulary-level controls (such as safety edits and quantity limits) at point-of-sale; (2) reviews of prior claims and clinical activity to identify at-risk beneficiaries; (3) case management outreach to beneficiaries' prescribers and pharmacies; and (4) beneficiary-level point-of-sale claim edits, if necessary to prevent continued overutilization of opioids. Lastly, Part D plan sponsors that have concluded that such point-of-sale edits are appropriate are expected to share information with a new sponsor when the beneficiary moves to another plan in accordance with applicable law.

A comparison of overutilization shows a significant reduction of opioid and acetaminophen overutilization in Part D since the overutilization policy went into effect. From 2011 through 2014, the number of potential opioid overutilizers, based on the CMS definition in the OMS, decreased by approximately 26 percent, or 7,500 beneficiaries.¹ In addition, from 2011 through 2014, the number of beneficiaries identified as potential acetaminophen overutilizers, based on the CMS definition in the OMS, decreased by more than 91 percent, or 70,000 beneficiaries.²

2. What is CMS doing to prevent diversion of Part D drugs?

Answer: Today, CMS requires Part D plan sponsors to have drug utilization review systems, policies, and procedures designed to ensure that a review of the prescribed drug therapy is performed before each prescription is dispensed to an enrollee in a sponsor's Part D plan, typically at the point-of-sale or point of distribution.³

Additionally, CMS has begun to implement critical safeguards to make sure that only legitimate prescribers are prescribing covered drugs to Part D beneficiaries. In the past, CMS and plan sponsors were limited in their ability to target individual prescribers; however, the Affordable Care Act granted additional authority related to strengthening Medicare enrollment requirements. CMS finalized regulations to use this authority to require most prescribers of drugs paid for by

¹ There were 29,404 potential opioid overutilizers, (or 0.29 percent of all Part D opioid users) in 2011 and there were 21,838 potential opioid overutilizers, (0.18 percent of all Part D Opioid users) in 2014.

² There were 76,581 potential acetaminophen overutilizers, (or 0.81 percent of all Part D acetaminophen users), in 2011 and in 2014 there were 6,286 (0.06 percent of all Part D acetaminophen users) in 2014.

³ The Part D sponsor's concurrent drug utilization review program must include, but is not limited to, the following checks each time a prescription is dispensed: (1) screening for potential drug therapy problems due to therapeutic duplication; (2) age- or gender-related contraindications; (3) over-utilization and under-utilization; (4) drug-drug interactions; (5) incorrect drug dosage or duration of drug therapy; (6) drug-allergy contraindications; and (7) clinical abuse or misuse.

Part D to enroll in Medicare.⁴⁵ CMS will enforce this requirement starting on June 1, 2016. To allow enough time to enroll all prescribers, CMS is recommending that prescribers of Part D drugs enroll by January 1, 2016. Requiring prescribers to enroll in Medicare will help CMS make sure that Part D drugs are prescribed by qualified individuals, and will prevent prescriptions from excluded or already revoked prescribers from being filled.

CMS has also established its authority to remove prescribers from Medicare when they demonstrate abusive prescribing patterns.⁶ A revocation for abusive prescribing would be based on criteria that demonstrate a pattern of improper prescribing and would address situations where the prescribing was not in compliance with Medicare requirements or where there were patient safety issues involved. These new revocation authorities provide CMS with the ability to remove problematic prescribers from the Medicare program and prevent them from treating people with Medicare.

3. Just last year you spoke before the committee on CMS's efforts to tighten up enrollment. My concern is speaking on the issue of provider ID abuse – this illegal distribution of Medicare beneficiary or provider ID numbers is yet another way individuals can abuse the system and the trust of our seniors, costing us millions. Above all else, this is a crime.

a. Can you update us on what specific efforts your office has taken to enforce the law and avert this trend?

Answer: CMS takes seriously its responsibility to protect the identities of both Medicare providers and beneficiaries. When CMS receives a complaint that a beneficiary's identity may have been compromised, a beneficiary's ID number may be added to the Compromised Number Checklist (CNC) database. The CNC is a web-based system that allows direct entry and retrieval of compromised Medicare provider and beneficiary numbers by CMS and CMS contractors. A number may be considered "compromised" if it is stolen or misused. CMS uses the compromised numbers in the CNC database to inform sophisticated analytics through the Fraud Prevention System (FPS). The FPS screens all Medicare Part A and Part B claims prior to payment, running each claim against multiple models that create alerts as they identify claims and other data that suggest aberrant billing. The FPS uses compromised provider numbers as one of the data elements within FPS models. Based on the results, CMS focuses its investigative and administrative resources on those in the highest risk tier for fraud. Following investigations, CMS may take appropriate administrative action against a provider or supplier, including revoking a provider's or supplier's billing privileges, implementing a payment suspension,

⁴ Section 6405 of the Affordable Care Act requires that physicians and eligible professionals who order durable medical equipment, prosthetics, orthotics and supplies or certify home health care for beneficiaries be enrolled in Medicare. The statute also permits the Secretary to extend these Medicare enrollment requirements to physicians and eligible professionals who order or certify all other categories of Medicare items or services, including covered Part D drugs. Accordingly, CMS will require that physicians and eligible professionals who write prescriptions for covered Part D drugs must be enrolled in Medicare, or have a valid record of opting out of Medicare for their prescriptions to be covered under Part D.

⁵ <https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/MedicareProviderSupEnroll/Part-D-Prescriber-Enrollment-About.html>

⁶ See <http://www.gpo.gov/fdsys/pkg/FR-2014-05-23/pdf/2014-11734.pdf>.

implementing prepayment edits, requesting an overpayment, and/or referring the provider to law enforcement. CMS also provides education to beneficiaries urging them to protect their identities. This education conveys the need for beneficiaries to guard their Medicare number and not share their card, to review their Medicare Summary Notice to ensure that they and Medicare are only being charged for actual services, and to beware of sham marketing activities.

CMS is also taking additional measures to protect beneficiary ID numbers. To protect against identity theft and strengthen the security of millions of beneficiaries' personal information, the President's FY 2016 Budget proposes a \$50 million investment in FY 2016 for a multi-year process of removing social security numbers (SSNs) from beneficiaries' Medicare cards. As you are aware, the Medicare Access and CHIP Reauthorization Act of 2015 (P.L. 114-10) provides resources for the Secretary of Health and Human Services, in consultation with the Commissioner of Social Security, to establish "cost-effective" procedures to remove the SSN from Medicare cards, which will enable CMS to implement a significant GAO recommendation. By April 2019, CMS, other Federal Agencies and private-sector partners will eliminate the use of an individual's SSN as the primary identifier on Medicare cards to improve and better protect private health care and financial information and the payments associated with their Federal health care benefits and services. The President's FY 2016 Budget also includes a proposal to increase penalties for knowingly distributing Medicare, Medicaid, or CHIP beneficiary identification, or billing privileges. This proposal strengthens penalties for individuals other than beneficiaries who illegally distribute Medicare, Medicaid, and CHIP identification numbers, such as providers.

The Honorable Markwayne Mullin

1. **In 2014, 43 percent of Oklahomans enrolled in Medicare Part D received a commonly abused opioid. According to the supplemental data for a recent OIG report, Medicare Part D alone spent \$24 million on methadone in 2014. Now, this is behind drugs like OxyContin and Percocet, but why do we continue to spend millions of dollars on a medication that by CMS's own recommendation should not be used for the first line of defense for pain? Does CMS have any plans to rein in spending on this drug in particular?**

Answer: CMS shares your concern about prescription opioid misuse and the harm that opioid use disorders can cause. Addressing the opioid crisis is a top priority, and we are committed to evidence-informed interventions to turn the tide against opioid drug-related overdose and misuse. The Secretary's larger three-part initiative to address opioid-drug related overdoses and drug dependence includes providing further training and education resources to assist health professionals in making informed prescribing decisions.

CMS is committed to reducing overutilization while protecting beneficiary access to needed medications. Methadone is not covered for substance abuse treatment under Part D. Methadone may be an appropriate, clinically-indicated medication for some beneficiaries with severe chronic pain. While there are precautions and limitations associated with its use, methadone use for patients with cancer is addressed in the National Comprehensive Cancer Network's Adult Cancer Pain Guidelines, and the Centers for Disease Control and Prevention (CDC) addressed methadone use for chronic pain in the Common Elements in Guidelines for Prescribing Opioid for Chronic Pain. For the current plan year, a methadone product is included on nearly 98 percent of Part D formularies. Quantity-limit restrictions have been imposed on approximately two thirds of all formulary methadone products.

2. **Several members of the subcommittee brought up the OIG's recommendation to restrict certain beneficiaries who are at risk of abusing opioids to a limited number of pharmacies or prescribers. Are there potential risks when implementing a "lock-in" policy? In my district, we have recently been experiencing flooding and other natural disasters. In this type of situation, do you think such a policy could put patients at risk if they can't fill their prescriptions?**

Answer: We share your concern about protecting beneficiary access to needed medications. The FY 2016 President's Budget proposes to give the Secretary authority to establish a program in Medicare Part D that would require that at-risk beneficiaries only utilize certain prescribers and/or pharmacies to obtain controlled substance prescriptions, similar to the programs many states have implemented in Medicaid. Beneficiaries would still be able to obtain prescriptions for non-controlled substances (e.g., antibiotics) from other pharmacies. Further, the Administration's proposal would require that CMS ensure that beneficiaries retain reasonable access to Medicare services of adequate quality and that any restricted period for a given beneficiary could only last for a reasonable period of time. We look forward to working with you and other stakeholders to improve Part D program integrity while ensuring that beneficiaries maintain access to needed medications.

[Page 6 of the document is blank.]

Attachment 2—Member Requests for the Record

During the hearing, Members asked you to provide additional information for the record, and you indicated that you would provide that information. For your convenience, descriptions of the requested information are provided below.

The Honorable Tim Murphy

1. What steps is CMS taking to discover providers who are prescribing children psychotropic medications in cases where it isn't medically necessary?

Answer: CMS has been working over the past two years with its many partners, including the Medicaid Medical Directors Network (MMDN), as well as the Administration for Children and Families (ACF) and the Substance Abuse and Mental Health Services Administration (SAMHSA), to strengthen oversight and monitoring of psychotropic medications use among children. Examples of these efforts include:

- Issuing guidance in a 2013 State Medicaid Director letter⁷ concerning the safe, appropriate and effective use of these medications among children;
- Organizing a two day state summit in August 2012, "*Because Minds Matter: Collaborating to Strengthen Psychotropic Medication Management for Children and Youth in Foster Care*," that brought together child welfare, mental health and Medicaid leaders from across the country to address the issue;
- Releasing a CMS Informational Bulletin in August 2012 that encouraged states to use "drug utilization review" to address the use of psychotropic medications in vulnerable populations and provided states with additional tools to promote the appropriate use and enhanced oversight of psychotropic medications for children in foster care;⁸
- Promoting patient safety and sharing best practices by surveying states annually and publishing specifics of their programs to manage/monitor the appropriate use of psychotropic drugs in children in addition to their innovative practices on www.medicaid.gov;⁹
- Posting on [Medicaid.gov](http://www.medicaid.gov) the FY 2013 Medicaid Drug Utilization Review State Comparison/Summary Annual Report, which describes state practice in monitoring use of psychotropic medications among children. The summary shows that: 41 states have programs in place to monitor the use of psychotropic medications in children; 37 states monitor all children (not just those children in foster care); and 41 states have restrictions or special programs in place to monitor/control the use of stimulants.¹⁰

⁷ <http://www.medicaid.gov/Federal-Policy-Guidance/Downloads/SMD-13-07-11.pdf>

⁸ <http://www.medicaid.gov/Federal-Policy-Guidance/downloads/CIB-08-24-12.pdf>

⁹ <http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Drug-Utilization-Review.html>

¹⁰ <http://www.medicaid.gov/medicaid-chip-program-information/by-topics/benefits/prescription-drugs/downloads/dur-survey-comparison-report-2013.pdf>

The President's FY 2016 Budget also includes a five-year demonstration, a collaboration between Medicaid and the Administration for Children and Families, beginning in FY 2016 to encourage states to implement evidence-based psychosocial interventions targeting children and youth in the foster care system. This transformational approach will include the development and scaling up of screening, assessment, and evidence-based treatment of trauma and mental health disorders among children and youth in foster care in order to reduce the reliance on psychotropic medications and improve child and family well-being. CMS would invest \$500 million in incentive payments to states that demonstrate measured improvement in outcomes.

2. Does CMS have a report, or is CMS aware of a report, that studies price increases in Medicare Part D and any corresponding decreases in hospitalizations or doctor visits?

Answer: CMS has not produced a report that directly examines the correlation between drug prices and utilization of health care services. However, studies show that increases in patient costs for medication are significantly associated with decreases in treatment adherence,¹¹ and other studies indicate that poor adherence leads to increased use of other health care services, such as hospitalizations.¹²

¹¹ <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278192/>

¹² http://avalere.com/research/docs/20130612_NACDS_Medication_Adherence.pdf

The Honorable Michael C. Burgess**1. Has the \$18 million paid to Dr. Tariq Mahood for fraudulent EHR system development been recovered?**

Answer: As you know, Dr. Mahmood was convicted for health care fraud and sent to prison, and his CFO has been convicted for making a false statement about Medicare Electronic Health Records (EHR) payments and sent to prison.¹³

As part of our oversight of the Electronic Health Record (EHR) Incentive Programs established under the HITECH Act, CMS conducts audits of professionals and hospitals that demonstrate meaningful use of certified EHR technology under Medicare. CMS conducted Medicare EHR Meaningful Use audits for six hospitals associated with Dr. Mahmood, in 2013. Based on the audits, it was determined that all six hospitals did not meet the Meaningful Use criteria. CMS issued demand letters for approximately \$12.1 million. CMS collected \$700,000. Consistent with CMS policy, approximately \$11.4 million of the identified debt was referred to Treasury for collection. An additional approximately \$700,000 has been collected by Treasury through this process. With accrued interest, the current balance at Treasury is about \$12.2 million.

The same six hospitals also received approximately \$5.6 million in incentive payments through the Medicaid EHR Incentive Program. Each state administers its own Medicaid EHR Incentive Program, which includes disbursing and recouping payments as appropriate. According to the state of Texas, they did not recover any EHR funds from these hospitals.

¹³

<http://www.justice.gov/usao-edtx/pr/texas-doctor-sentenced-prison-health-care-fraud-scheme>
<https://www.fbi.gov/dallas/press-releases/2015/former-shelby-county-hospital-cfo-sentenced-in-ehr-incentive-case>

The Honorable Yvette Clarke**1. How does CMS evaluate the effectiveness of sponsor's compliance programs?**

- a. Have these efforts changed recently?**
- b. What is CMS doing to follow up with audited plans to ensure that identified deficiencies are being remedied?**

Answer: CMS conducts annual audits of Medicare Part D plan sponsors' compliance programs, as well as other core program functions relating to access to care and medications. The compliance program effectiveness audits evaluate the plan sponsor's infrastructure around monitoring, identifying, and correcting their own operations to ensure compliance with CMS requirements. CMS validates correction of deficiencies identified during an audit before closing the audit. In the event that a Part D Sponsor performs poorly during an audit, CMS can take a variety of compliance and enforcement actions. These range from notices of non-compliance to terminating a Sponsor's Part D contract, with civil money penalties being the most common outcome of poor audit results.

In 2014, based on two recommendations from the OIG, CMS piloted audits of Part D sponsor's programs to address fraud and abuse. These program integrity activities are recorded in the sponsor's 'Compliance Plans'. As a result of those pilots, in 2015 CMS incorporated a review of program integrity activities into the audits of Sponsor Compliance Plans that CMS conducts annually. Now, every CMS Part D sponsor audit includes an analysis of whether their efforts to address fraud and abuse are working effectively. We specifically review cases of reported fraud and look at the sponsors' follow up actions; the results of these reviews provide an indication of the plan sponsor's overall performance and allow us to target guidance and education.

The Honorable David McKinley

1. Please provide the year-to-year Medicare Part D error rate for all years for which CMS has error rate data.

Answer: It is important to note that an error rate is not a “fraud rate” but simply a measurement of payments made that did not meet statutory, regulatory or administrative requirements. CMS began reporting a payment error measure for the Part D Program in 2011. For the Part D program, CMS reports a composite improper payment error rate estimate based on final Part D payments made two years prior (e.g. FY 2011 represents final Part D payments made for 2009 claims). CMS expects to release its FY2015 (based on CY 2013 payments) later this year.

Year	Improper Payment Rate
FY 2011 (Based on Calendar Year 2009 payments final Part D payments)	3.2%
FY 2012 (Based on CY 2010 final Part D payments)	3.1%
FY 2013 (Based on CY 2011 final Part D payments)	3.7%
FY 2014 (Based on CY 2012 final Part D payments)	3.3%

FRED UPTON, MICHIGAN
CHAIRMAN

FRANK PALLONE, JR., NEW JERSEY
RANKING MEMBER

ONE HUNDRED FOURTEENTH CONGRESS
Congress of the United States
House of Representatives
COMMITTEE ON ENERGY AND COMMERCE
2125 RAYBURN HOUSE OFFICE BUILDING
WASHINGTON, DC 20515-6115
Majority (2021) 225-2927
Minority (2021) 225-3641

August 5, 2015

Ms. Ann Maxwell
Assistant Inspector General
Office of Inspector General
U.S. Department of Health and Human Services
330 Independence Avenue, S.W.
Washington, D.C. 20201

Dear Ms. Maxwell:


Thank you for appearing before the Subcommittee on Subcommittee on Oversight and Investigations on Tuesday, July 14, 2015, to testify at the hearing entitled "Medicare Part D: Measures Needed to Strengthen Program Integrity."

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

Also attached are Member requests made during the hearing. The format of your responses to these requests should follow the same format as your responses to the additional questions for the record.

To facilitate the printing of the hearing record, please respond to these questions and requests with a transmittal letter by the close of business on Wednesday, August 19, 2015. Your responses should be mailed to Jessica Wilkerson, Oversight Associate, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, D.C. 20515 and e-mailed in Word format to Jessica.wilkerson@mail.house.gov.

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,

Tim Murphy
Chairman
Subcommittee on Oversight and Investigations

cc: Dianna DeGette, Ranking Member, Subcommittee on Oversight and Investigations

Attachments



DEPARTMENT OF HEALTH AND HUMAN SERVICES
OFFICE OF INSPECTOR GENERAL
WASHINGTON, DC 20201



AUG 19 2015

The Honorable Tim Murphy
Committee on Energy and Commerce
Subcommittee on Oversight and Investigations
United States House of Representatives
Washington, DC 20515

Dear Mr. Chairman:

I am writing in response to your August 5, 2015, letter containing questions for the record from Representative Susan Brooks and Representative Michael Burgess following my testimony before the Subcommittee on Oversight and Investigations on Tuesday, July 14, 2015, at the hearing entitled "Medicare Part D: Measures Needed to Strengthen Program Integrity."

If you have any questions, please contact me or your staff may contact Christopher Seagle, Director of External Affairs, at (202) 260-7006 or Christopher.Seagle@oig.hhs.gov.



Ann Maxwell
Assistant Inspector General

cc: Representative Dianna DeGette, Ranking Member, Subcommittee on Oversight and Investigations

Enclosures:
Responses to QFR's from Representative Brooks and Representative Burgess

Ann Maxwell, Assistant Inspector General, Office of Inspector General, U.S. Department of Health and Human Services, response to question for the record following "Medicare Part D: Measures Needed to Strengthen Program Integrity"

The Honorable Michael C. Burgess: QFR from the July 13, 2015, hearing before the House Energy and Commerce Subcommittee on Oversight and Investigations regarding Medicare Part D issues.

"Has the \$18 million paid to Dr. Tariq Mahmood for fraudulent EHR system development been recovered?"

OIG investigated a case on Dr. Mahmood who was later convicted of conspiracy, health care fraud, and aggravated identity theft. These convictions were primarily related to health care billing matters and identity theft (as opposed to EHR Meaningful Use payments). Dr. Mahmood was sentenced in April 2015 to 139 months in Federal prison and ordered to pay restitution in the amount of \$599,128. The OIG case is now closed. Dr. Mahmood

Sentencing: <http://www.justice.gov/usao-edtx/pr/texas-doctor-sentenced-prison-health-care-fraud-scheme>

However, OIG additionally investigated a case on Joe White, the Chief Financial Officer of Shelby County Hospital (owned by Dr. Mahmood), regarding Medicare EHR Incentive Program funds. Mr. White pleaded guilty and in June 2015 was sentenced to 23 months in Federal prison and ordered to pay restitution in the amount of \$4,483,089 to Medicare's EHR Incentive Program. The OIG case is now closed. Joe White Sentencing: <http://www.justice.gov/usao-edtx/pr/former-shelby-county-hospital-cfo-sentenced-ehr-incentive-case>

Since the funds were ordered back to Medicare's EHR Incentive Program that CMS administers (<http://www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/index.html?redirect=/EHRIncentivePrograms/>), they are the best source to answer Rep. Burgess's question about whether the funds were returned.

Ann Maxwell, Assistant Inspector General, Office of Inspector General, U.S. Department of Health and Human Services, response to question for the record following "Medicare Part D: Measures Needed to Strengthen Program Integrity"

The Honorable Susan W. Brooks: QFR from the July 14, 2015, hearing before the House Energy and Commerce Subcommittee on Oversight and Investigations regarding Medicare Part D issues.

"Since the Part D program went into effect in 2006, the Office of Inspector General (OIG) has had ongoing concerns about abuse and diversion of Part D drugs. What is the basis for these concerns? Is there data to support this concern?"

In the 9 years since Part D began, OIG has produced a wide range of investigations, legal guidance, audits, and evaluations related to fraud, waste, and abuse in Part D. OIG work has revealed questionable billing associated with pharmacies, prescribers, and beneficiaries involving both controlled and non-controlled substances. A recent OIG report found that spending for Part D drugs has more than doubled since 2006. Further, OIG found that spending for commonly abused opioids grew faster than spending for all Part D drugs (from \$1.5 billion to \$3.9 billion) between 2006 and 2014. This growth appears to have been driven by an increase in both the number of beneficiaries receiving these opioids and in the average number of prescriptions per beneficiary.

Yes, there is data that supports OIG's concern regarding the abuse and diversion of Part D drugs. OIG's work relies upon many sources, including but not limited to interviews, discussions with Department employees, claims data, and review of policies and procedures. OIG work has identified thousands of retail pharmacies with questionable billing, including billing for extremely high numbers of prescriptions per beneficiary or per prescriber. OIG has also identified questionable Part D payments for (1) drugs ordered by individuals without the authority to prescribe, such as athletic trainers and massage therapists; (2) refills of Schedule II drugs, which are prohibited by Federal law; and (3) claims for HIV drugs for beneficiaries with no indication of HIV in their medical histories, who received an excessive dose or supply of HIV drugs, received HIV drugs from a high number of pharmacies or prescribers, or received HIV drugs that should not be used in combination with one another. Although some of this billing may be legitimate, all of these payments warrant further scrutiny, as inappropriate claims may be associated with abuse and diversion of both controlled and non-controlled prescription drugs.

OIG has conducted Part D investigations that resulted in 339 criminal actions, 31 civil actions, and over \$720 million in investigative receivables from 2012 to 2014. These investigations have identified criminal enterprises committing health care fraud and medical identity theft. OIG investigations have also identified beneficiaries who act as perpetrators of fraud by reselling their prescription medications to drug-trafficking organizations. These cases serve as confirmation that drug diversion has occurred in Part D.

Ann Maxwell, Assistant Inspector General, Office of Inspector General, U.S. Department of Health and Human Services, response to question for the record following "Medicare Part D: Measures Needed to Strengthen Program Integrity"

The results of OIG's data analyses and investigations serve as the basis for OIG's concerns about drug abuse and diversion. OIG will continue to monitor these vulnerabilities, as well as any other emerging program integrity issues in Part D.